<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002007.pub4" GROUP_ID="CF" ID="005399120911435692" MERGED_FROM="" MODIFIED="2016-12-01 11:51:15 +0000" MODIFIED_BY="Nikki Jahnke" REVIEW_NO="0030" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="15.0">
<COVER_SHEET MODIFIED="2016-12-01 11:51:13 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE MODIFIED="2016-09-26 08:02:42 +0100" MODIFIED_BY="Nikki Jahnke">Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis</TITLE>
<CONTACT MODIFIED="2016-12-01 11:51:13 +0000" MODIFIED_BY="Nikki Jahnke"><PERSON ID="11668" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Elphick</LAST_NAME><EMAIL_1>H.Elphick@sheffield.ac.uk</EMAIL_1><EMAIL_2>Heather.Elphick@sch.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Respiratory Unit</DEPARTMENT><ORGANISATION>Sheffield Children's Hospital</ORGANISATION><ADDRESS_1>Western Bank</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S10 2TH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 271 7369</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-12-01 11:51:13 +0000" MODIFIED_BY="Nikki Jahnke"><PERSON ID="11668" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Heather</FIRST_NAME><MIDDLE_INITIALS>E</MIDDLE_INITIALS><LAST_NAME>Elphick</LAST_NAME><EMAIL_1>H.Elphick@sheffield.ac.uk</EMAIL_1><EMAIL_2>Heather.Elphick@sch.nhs.uk</EMAIL_2><ADDRESS><DEPARTMENT>Respiratory Unit</DEPARTMENT><ORGANISATION>Sheffield Children's Hospital</ORGANISATION><ADDRESS_1>Western Bank</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S10 2TH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 114 271 7369</PHONE_1></ADDRESS></PERSON><PERSON ID="z1405010855432339308191730533549" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alison</FIRST_NAME><LAST_NAME>Scott</LAST_NAME><POSITION>Consultant in Paediatric Respiratory Medicine</POSITION><EMAIL_1>Alison.Scott@sch.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Respiratory Unit</DEPARTMENT><ORGANISATION>Sheffield Children's Hospital</ORGANISATION><ADDRESS_1>Western Bank</ADDRESS_1><CITY>Sheffield</CITY><ZIP>S10 2TH</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-11-23 15:20:06 +0000" MODIFIED_BY="Nikki Jahnke">
<UP_TO_DATE>
<DATE DAY="14" MONTH="10" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="10" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="11" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-11-23 15:20:15 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-11-23 15:20:15 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="10" YEAR="2016"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Review Group's Cystic Fibrosis Trials Register identified three new references that were potentially eligible for inclusion in the review.</P>
<P>One reference was an additional reference to an already excluded trial (<LINK REF="STD-Blumer-2005" TYPE="STUDY">Blumer 2005</LINK>); the remaining two references to two trials were also excluded (<LINK REF="STD-Prayle-2013" TYPE="STUDY">Prayle 2013</LINK>; <LINK REF="STD-Turner-2013" TYPE="STUDY">Turner 2013</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-10-27 09:17:23 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="14" MONTH="10" YEAR="2016"/>
<DESCRIPTION>
<P>Dr Alison Scott has replaced Nikki Jahnke on the review team. </P>
<P>The review title has been amended to reflect that the therapies included focus on anti-pseudomonal antibiotics.</P>
<P>No new data were added to the review at this update, therefore our conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-02-22 13:02:51 +0000" MODIFIED_BY="Nikki Jahnke">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-02-22 13:02:51 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="29" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>The previous co-author, Dr Anton Tan, has stepped down and a new co-author, Nikki Jahnke, has joined the review team. </P>
<P>No new references have been added to this review, hence the conclusions remain the same.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-02-22 13:02:48 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="29" MONTH="4" YEAR="2014"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Cystic Fibrosis Trials Register identified seven references to six potentially eligible studies all of which were excluded from the review (<LINK REF="STD-Beringer-2012" TYPE="STUDY">Beringer 2012</LINK>; <LINK REF="STD-Blumer-2005" TYPE="STUDY">Blumer 2005</LINK>; <LINK REF="STD-Hatziagorou-2013" TYPE="STUDY">Hatziagorou 2013</LINK>; <LINK REF="STD-Keel-2011" TYPE="STUDY">Keel 2011</LINK>; <LINK REF="STD-McCabe-2013" TYPE="STUDY">McCabe 2013</LINK>; <LINK REF="STD-Semykin-2010" TYPE="STUDY">Semykin 2010</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-08-27 15:39:44 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="17" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-10-17 13:20:01 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="3" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified 15 new references potentially eligible for inclusion in this review. However, none of the references were suitable for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-08-25 15:06:58 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="9" YEAR="2009"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Register identified no new references which were potentially eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-09-15 12:01:49 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified no new references eligible for inclusion in this review.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-15 12:01:51 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="11" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-11 12:45:09 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="20" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>The 'Plain Language Summary' has been updated in line with latest guidance from The Cochrane Collaboration.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 12:45:11 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="20" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified no new references eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 12:52:12 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="21" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified no new references eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 12:52:46 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="15" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified no new references.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 12:54:33 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="9" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>A search of the Group's Cystic Fibrosis Trials Register identified no new references.</P>
<P>One previously included trial has now been excluded from the review (Padoan 1987). In this trial a total of 40 courses of treatment took place (20 in each intervention group). The trial was cross-over in design, however, re-randomisation took place between courses of treatment, resulting in some participants possibly receiving two or more courses of the same treatment, or a mixture of different treatments. Since the number of participants receiving each treatment was unclear, results could not be included in the analysis of this review and therefore the trial was excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="9" MONTH="2" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-11 12:54:13 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="13" MONTH="11" YEAR="2002"/>
<DESCRIPTION>
<P>Excluded Studies:</P>
<P>One additional study has been added - Krause 1979 .<BR/>An additional reference to the Nelson 1985 study has also been included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-02-22 13:09:08 +0000" MODIFIED_BY="Nikki Jahnke">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-02-22 13:09:08 +0000" MODIFIED_BY="Nikki Jahnke">
<SOURCE MODIFIED="2016-02-22 13:09:08 +0000" MODIFIED_BY="Nikki Jahnke">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-12-01 11:48:29 +0000" MODIFIED_BY="Nikki Jahnke">
<SUMMARY MODIFIED="2016-12-01 11:43:51 +0000" MODIFIED_BY="Nikki Jahnke">
<TITLE MODIFIED="2016-12-01 11:43:51 +0000" MODIFIED_BY="Nikki Jahnke">A comparison of single and combined intravenous drug therapy for people with cystic fibrosis infected with <I>Pseudomonas aeruginosa</I>
</TITLE>
<SUMMARY_BODY MODIFIED="2016-11-23 15:20:34 +0000" MODIFIED_BY="Nikki Jahnke">
<P>
<B>Review question</B>
</P>
<P>We reviewed the evidence about the different effects of using a single intravenous (given directly into a vein) antibiotic compared to using a combination of intravenous antibiotics in people with cystic fibrosis infected with <I>Pseudomonas aeruginosa</I>.</P>
<P>
<B>Background</B>
</P>
<P>Cystic fibrosis is a serious genetic disease that affects cells in the exocrine glands (sweat glands and others). People with cystic fibrosis have a greater risk of chronic lung infections, often due to bacteria called <I>Pseudomonas aeruginosa</I>. They receive antibiotics, either a single drug or a combination of different drugs, by injection to treat these infections. Both the choice of antibiotic and the use of single or combined therapy vary. We looked for randomised controlled trials which compared a single intravenous antibiotic with a combination of that antibiotic plus another one in people with cystic fibrosis. This is an updated version of the review.</P>
<P>
<B>Search date</B>
</P>
<P>The evidence is current to: 14 October 2016.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We included eight trials with a total of 356 people. Six of these were published before 1988, were each based in a single centre and used a range of different drugs. These factors made it difficult to combine and analyse the results.</P>
<P>
<B>Key results</B>
</P>
<P>We did not find any differences between the two therapies for lung function, symptom scores, side effects or bacteriological outcome measures. We conclude that there is not enough evidence to compare the different therapies. More research is needed, particularly looking at side effects of treatment.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Six of the included trials were quite old (published between 1977 and 1988). They did not include many people and had flaws in the way the people taking part were put into the different treatment groups. Overall, the quality of the trials' design was poor.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-11-23 15:20:27 +0000" MODIFIED_BY="Nikki Jahnke">
<ABS_BACKGROUND MODIFIED="2016-11-23 15:20:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Choice of antibiotic, and the use of single or combined therapy are controversial areas in the treatment of respiratory infection due to <I>Pseudomonas aeruginosa</I> in cystic fibrosis (CF). Advantages of combination therapy include wider range of modes of action, possible synergy and reduction of resistant organisms; advantages of monotherapy include lower cost, ease of administration and reduction of drug-related toxicity. Current evidence does not provide a clear answer and the use of intravenous antibiotic therapy in cystic fibrosis requires further evaluation. This is an update of a previously published review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-11-23 15:20:22 +0000" MODIFIED_BY="Nikki Jahnke">
<P>To assess the effectiveness of single compared to combination intravenous anti-pseudomonal antibiotic therapy for treating people with cystic fibrosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-10-27 09:19:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.</P>
<P>Most recent search of the Group's Trials Register: 14 October 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-11-23 15:20:27 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Randomised controlled trials (RCTs) comparing a single intravenous anti-pseudomonal antibiotic with a combination of that antibiotic plus a second anti-pseudomonal antibiotic in people with CF.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two authors independently assessed trial quality and extracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-11-23 15:20:27 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We identified 45 trials, of which eight trials (356 participants) comparing a single anti-pseudomonal agent to a combination of the same antibiotic and one other, were included.</P>
<P>There was a wide variation in the individual antibiotics used in each trial. In total, the trials included seven comparisons of a beta-lactam antibiotic (penicillin-related or third generation cephalosporin) with a beta-lactam-aminoglycoside combination and three comparisons of an aminoglycoside with a beta-lactam-aminoglycoside combination. These two groups of trials were analysed as separate subgroups.</P>
<P>There was considerable heterogeneity amongst these trials, leading to difficulties in performing the review and interpreting the results. The meta-analysis did not demonstrate any significant differences between monotherapy and combination therapy, in terms of lung function; symptom scores; adverse effects; and bacteriological outcome measures.</P>
<P>These results should be interpreted cautiously. Six of the included trials were published between 1977 and 1988; these were single-centre trials with flaws in the randomisation process and small sample size. Overall, the methodological quality was poor.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The results of this review are inconclusive. The review raises important methodological issues. There is a need for an RCT which needs to be well-designed in terms of adequate randomisation allocation, blinding, power and long-term follow up. Results need to be standardised to a consistent method of reporting, in order to validate the pooling of results from multiple trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-12-01 11:48:29 +0000" MODIFIED_BY="Nikki Jahnke">
<BACKGROUND MODIFIED="2016-12-01 11:46:16 +0000" MODIFIED_BY="Nikki Jahnke">
<CONDITION MODIFIED="2016-12-01 11:46:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Cystic fibrosis (CF) is the most common life-limiting inherited disorder affecting white populations, with chronic, progressive lung disease being the major cause of morbidity and shortened survival. The continuous cycle of infection and inflammation is responsible for the severe airway damage and loss of respiratory function (<LINK REF="REF-Cantin-1995" TYPE="REFERENCE">Cantin 1995</LINK>; <LINK REF="REF-Konstan-1997" TYPE="REFERENCE">Konstan 1997</LINK>).</P>
<P>Recurrent infection, in particular with <I>Pseudomonas aeruginosa</I> (<I>P aeruginosa</I>) is the main feature of the lung involvement in CF. Administration of intravenous (IV) antibiotic therapy for a period of around two weeks is standard practice for treatment of pulmonary infections in most CF centres. Some studies have shown this approach to be effective in improving sputum colony counts (<LINK REF="REF-Regelmann-1990" TYPE="REFERENCE">Regelmann 1990</LINK>). Regular, elective IV therapy, as well as other interventions such as early treatment and cohorting have been shown to have a beneficial effect on the prevalence of <I>P aeruginosa</I> (<LINK REF="REF-Frederiksen-1999" TYPE="REFERENCE">Frederiksen 1999</LINK>). However, this relationship was not demonstrated in a small study by Wolter (<LINK REF="REF-Wolter-1999" TYPE="REFERENCE">Wolter 1999</LINK>). The inconsistency of these results suggests that the use of this therapy requires further evaluation.</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-11-23 15:20:53 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Currently, treatment of chronic <I>P aeruginosa </I>infection in people with CF usually involves one of the following strategies. One approach is to use IV antibiotics to treat people with CF only when they become acutely unwell, on the grounds of clinical, radiological or pulmonary function parameters (subsequently referred to as symptomatic regimen). Alternatively, chronic infection may be treated with elective IV antibiotics at regular intervals (e.g. three-monthly) (<LINK REF="REF-Hoiby-1993" TYPE="REFERENCE">Hoiby 1993</LINK>), to try to prevent long-term deterioration (subsequently referred to as elective regimen). Trials using either of these strategies will be considered for this review, if the same strategy was used for treatment and comparison groups.</P>
<P>Choice of antibiotic, single or combined therapy and the duration of treatment are controversial areas in the treatment of infection with IV antibiotics in CF. Current practice in the UK is variable, with one study from 1993 showed 80% choosing a combination and 20% using monotherapy (<LINK REF="REF-Taylor-1993" TYPE="REFERENCE">Taylor 1993</LINK>). However, more recently it was reported that monotherapy is now used in only 1 out of 23 centres in the UK who replied to a postal survey (<LINK REF="REF-Tan-2002" TYPE="REFERENCE">Tan 2002</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-12-01 11:44:13 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Most centres perceive dual or combination IV antibiotic therapy in CF to be more effective than single therapy. It has been suggested that a clinic policy of using monotherapy with a beta-lactam antibiotic may be responsible for the emergence of resistant strains of <I>P aeruginosa </I>(<LINK REF="REF-Cheng-1996" TYPE="REFERENCE">Cheng 1996</LINK>). Use of a beta-lactam alone offers advantages for the individual because of ease of administration and avoidance of the need to measure aminoglycoside levels.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-02-22 13:54:11 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Intravenous antibiotic therapy may have contributed to improved survival among people with CF; however, the multiple use of potent and highly selective antibiotics may increase the likelihood of adverse effects and lead to the development of resistant strains of organisms (<LINK REF="REF-Levy-1998" TYPE="REFERENCE">Levy 1998</LINK>). This version of the review is an update of previous review versions (<LINK REF="REF-Elphick-2002" TYPE="REFERENCE">Elphick 2002</LINK>; <LINK REF="REF-Elphick-2005" TYPE="REFERENCE">Elphick 2005</LINK>; <LINK REF="REF-Elphick-2014" TYPE="REFERENCE">Elphick 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-11-23 15:20:58 +0000" MODIFIED_BY="Nikki Jahnke">
<P>1. To assess the effectiveness of single compared to combination IV anti-pseudomonal antibiotic therapy in the treatment of people with CF.<BR/>2. To assess whether the use of combination IV anti-pseudomonal antibiotic therapy leads to an increase in adverse effects or the development of resistant strains of organisms in CF.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-12-01 11:44:48 +0000" MODIFIED_BY="Nikki Jahnke">
<SELECTION_CRITERIA MODIFIED="2016-12-01 11:44:48 +0000" MODIFIED_BY="Nikki Jahnke">
<CRIT_STUDIES>
<P>Randomised controlled trials. Trials in which individuals are treated according to a symptomatic or an elective regimen (see above) were included if the only difference between the treatment and comparison group is whether the participants receive single or combination antibiotic therapy. Trials where quasi-randomisation methods such as alternation were used were included, when there was sufficient evidence that the treatment and comparison groups were comparable in terms of clinical status. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children and adults with defined CF diagnosed clinically and by sweat or genetic testing including all ages and all degrees of severity.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-11-23 15:21:07 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Any single IV anti-pseudomonal antibiotic compared to a combination of two or more IV anti-pseudomonal antibiotics. Trials comparing a single anti-pseudomonal agent to a combination of the same antibiotic and one other anti-pseudomonal agent (drug A versus drug A plus drug B) were included. Trials which compared a single anti-pseudomonal antibiotic agent with a combination of two further anti-pseudomonal antibiotics (drug A versus drug B plus drug C) were not included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-12-01 11:44:48 +0000" MODIFIED_BY="Nikki Jahnke">
<P>We aimed to assess whether a combination of IV anti-pseudomonal antibiotics is more effective than a single IV anti-pseudomonal antibiotic for the following outcomes:</P>
<OL>
<LI>subjective improvement;</LI>
<LI>clinical improvement;</LI>
<LI>bacteriological improvement;</LI>
<LI>adverse effects.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">Short-term results</HEADING>
<P>(i.e. at end of course of antibiotics)</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<OL>
<LI>Clinical improvement</LI>
<OL>
<LI>improvement in spirometric lung function (e.g. forced expiratory volume in one second (FEV<SUB>1</SUB>) and forced vital capacity (FVC))</LI>
</OL>
<LI>Bacteriological improvement</LI>
<OL>
<LI>improvement in quantitative bacteriology of sputum</LI>
</OL>
<LI>Adverse effects to antibiotics, e.g. renal and auditory impairment, serum sickness and sensitivity reactions</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Subjective improvement</LI>
<OL>
<LI>quality of life assessment, in terms of measures of the individual's well-being</LI>
</OL>
<LI>Clinical improvement</LI>
<OL>
<LI>nutritional status as noted by weight gain, body mass index, z score or other indices of nutritional state</LI>
<LI>additional treatment required</LI>
<LI>duration of hospitalisation</LI>
<LI>time to next course of IV antibiotics</LI>
<LI>chest X-ray (CXR) scores</LI>
<LI>improvement in symptoms</LI>
</OL>
<LI>Bacteriological improvement</LI>
<OL>
<LI>Changes in inflammatory markers (in sputum or blood)</LI>
</OL>
</OL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Long-term results</HEADING>
<P>(measured at 6 to 12 months after course of antibiotics; if long-term outcomes are measured at other time intervals, consideration will be given to these also)</P>
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes</HEADING>
<OL>
<LI>Clinical improvement</LI>
<OL>
<LI>prevention of deterioration of lung function</LI>
</OL>
<LI>Bacteriological change</LI>
<OL>
<LI>development of antibiotic-resistant strains of<I> P aeruginosa </I>and other organisms</LI>
</OL>
<LI>Adverse effects to antibiotics, e.g. renal and auditory impairment, serum sickness and sensitivity reactions</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes</HEADING>
<OL>
<LI>Subjective improvement</LI>
<OL>
<LI>quality of life assessment</LI>
</OL>
<LI>Clinical improvement</LI>
<OL>
<LI>number of courses of IV antibiotics in the following year</LI>
</OL>
</OL>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-10-27 09:20:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Relevant trials were identified from the Group's Cystic Fibrosis Trials Register using the terms: antibiotics AND intravenous.</P>
<P>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (Clinical Trials) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals - <I>Pediatric Pulmonology </I>and the <I>Journal of Cystic Fibrosis</I>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Group's CF Trials Register: 14 October 2016.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-11-23 15:21:26 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_SELECTION MODIFIED="2008-09-11 13:06:15 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Two authors from different centres independently reviewed all trials to select which were to be included in the review. If disagreement arose on the suitability of a trial for inclusion in the review, the authors reached a consensus by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-02-22 13:37:28 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Each author independently extracted data using standard data acquisition forms. If disagreement arose on the quality of a trial, the authors reached a consensus by discussion.</P>
<P>If there had been sufficient numbers of trials using quasi-randomisation methods, then the authors would have analysed this group separately.</P>
<P>The authors grouped data into short-term results and long-term results. They defined short-term results as those at the end of the course of antibiotics; they considered long-term results to be 6 to 12 months after the course of antibiotics. The authors will also consider other time intervals for long-term outcomes if these are reported.</P>
<P>For binary outcome measures the authors recorded the number of events and the number of participants for each group. For continuous outcomes, the authors recorded either the mean change from baseline for each group or mean post-treatment or intervention values and the standard deviation or standard error for each group.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-02-22 13:38:28 +0000" MODIFIED_BY="Nikki Jahnke">
<P>In order to establish a risk of bias for each trial, the authors independently assessed the methodological quality of each trial. In particular, authors examined details of the randomisation method (generation and concealment of allocation), the degree of blinding in the trial, whether intention-to-treat analyses were possible from the available data and if the investigators recorded the number of participants lost to follow up or subsequently excluded from the trial.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-02-22 13:39:11 +0000" MODIFIED_BY="Nikki Jahnke">
<P>For binary outcome measures, the authors calculated a pooled estimate of the treatment effect for each outcome across trials using the Peto odds ratio with 95% confidence intervals (CIs) where appropriate. For continuous outcomes, the authors calculated a pooled estimate of treatment effect by calculating the mean difference with 95% CIs.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-02-22 13:39:32 +0000" MODIFIED_BY="Nikki Jahnke">
<P>One trial included in the review was of cross-over design (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). Ideally when conducting a meta-analysis combining results from cross-over trials the authors would have liked to use the inverse variance methods that are recommended by Elbourne (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). However, due to restrictions on the data that were available from the included trial, the only method that they have been able to use was to treat the cross-over trial as if it was a parallel trial (assuming a correlation of zero as the most conservative estimate). Elbourne says that this approach produces conservative results as it does not take into account within-patient correlation (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Also each participant appears in both the treatment and control group, so the two groups are not independent.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-09-11 13:07:24 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In order to allow an intention-to-treat analysis, the authors collected data on the number of participants with each outcome event by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-02-22 13:40:06 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The authors tested for heterogeneity between trial results using a standard Chi<SUP>2</SUP> test.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-11-10 12:50:05 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The authors analysed the data using a fixed-effect model. In future updates, if they identify a moderate to high degree of heterogeneity, they plan to analyse the data using a random-effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-11-23 15:21:26 +0000" MODIFIED_BY="Nikki Jahnke">
<P>If there were sufficient trials, the authors planned to carry out subgroup analyses of adults separately from children; of participants on a symptomatic regimen separately from those on an elective regimen; and also of those who were colonised with <I>P aeruginosa </I>(i.e. those people with CF who are sputum positive on three consecutive occasions) separately from those who were not colonised.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-11-10 12:50:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The authors planned to perform a sensitivity analysis based on the methodological quality of the trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-12-01 11:48:29 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY_DESCRIPTION MODIFIED="2016-12-01 11:44:59 +0000" MODIFIED_BY="Nikki Jahnke">
<SEARCH_RESULTS MODIFIED="2016-05-31 13:43:26 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A total of 45 trials were identified by the searches. No trials were found through contact with pharmaceutical companies. We included eight trials in the review and excluded 37 trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-12-01 11:44:59 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Eight trials (including 356 participants) were included in this review; of these three were published only as abstracts from conference proceedings (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>).</P>
<P>Seven trials were stated to be randomised controlled trials (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). The method of randomisation was stated in only one of these, in which it was described as "computer-generated" (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). In the remaining trial, treatment was assigned as an alternate allocation with good evidence of similar groups at baseline (<LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>). This trial was included as a quasi-randomised trial.</P>
<P>In seven of the eight trials, participants were included during an exacerbation of symptoms (symptomatic regimen) in a parallel group design (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). In the remaining trial, participants were treated using a three-monthly elective regimen and were re-entered into the trial during consecutive courses of antibiotics in a cross-over design (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). In five of the trials, evidence of <I>P aeruginosa </I>in the sputum was an inclusion requirement (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>; <LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>); of the remaining three trials, one stated that 98% had <I>P aeruginosa</I> (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>).</P>
<P>Criteria for diagnosis of CF were stated in only one of the eight trials (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). Sample sizes varied from 14 to 83 participants, with a total of 356 participants recruited. All trials either stated that they included both adults and children, or did not state the age range. No trial looked at the effects of single versus combination antibiotic therapy in children alone. One trial included 17 children, but included three children twice, giving a total of 20 treatment courses (<LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>).</P>
<P>There was a wide variation in the individual antibiotics used in each trial (<I>see</I> <LINK TAG="PUBLIC_NOTES" TYPE="SECTION">Published notes</LINK>: Description of pharmacological properties of antibiotics used). Two trials made two comparisons, therefore, in total, the eight trials included seven comparisons of a beta-lactam antibiotic (penicillin-related or third generation cephalosporin) to a beta-lactam-aminoglycoside combination and three comparisons of an aminoglycoside to a beta-lactam-aminoglycoside combination. These two groups of trials were analysed as separate subgroups.</P>
<P>Two trials compared two single agents with the combination of the same two antibiotics: carbenicillin versus sisomycin versus carbenicillin and sisomycin (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>); ticarcillin versus gentamicin versus ticarcillin and gentamicin (<LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>). One other trial looked at an aminoglycoside as the single agent: tobramycin versus tobramycin and ceftazidime (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>). Of the remaining five trials, one studied ceftazidime as the single agent (ceftazidime and tobramycin (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>)) and the remaining four compared an agent from the penicillin group of antibiotics: piperacillin (<LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>); ticarcillin (<LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>); azlocillin (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>) with a combination of that agent with tobramycin.</P>
<P>Outcomes were studied at the end of the treatment course in all trials. Treatment duration varied from 10 to 14 days. Three trials included a follow-up period, which varied from two to eight weeks (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>) to six months for the cross-over trial (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-05-31 13:44:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>A total of 37 trials were excluded. Eleven trials compared a single antibiotic agent with the existing combination of two other antibiotics (drug A versus drug B plus drug C) (<LINK REF="STD-Balsamo-1986" TYPE="STUDY">Balsamo 1986</LINK>; <LINK REF="STD-Beaudry-1980" TYPE="STUDY">Beaudry 1980</LINK>; <LINK REF="STD-Bosso-1988" TYPE="STUDY">Bosso 1988</LINK>; <LINK REF="STD-Church-1997" TYPE="STUDY">Church 1997</LINK>; <LINK REF="STD-De-Boeck-1989" TYPE="STUDY">De Boeck 1989</LINK>; <LINK REF="STD-De-Boeck-1999" TYPE="STUDY">De Boeck 1999</LINK>; <LINK REF="STD-Gold-1985" TYPE="STUDY">Gold 1985</LINK>; <LINK REF="STD-Jewett--1985" TYPE="STUDY">Jewett 1985</LINK>; <LINK REF="STD-Permin-1983" TYPE="STUDY">Permin 1983</LINK>; <LINK REF="STD-Stack-1985" TYPE="STUDY">Stack 1985</LINK>; <LINK REF="STD-Wesley-1988" TYPE="STUDY">Wesley 1988</LINK>). Fourteen trials compared different dosage regimens of the same antibiotic (<LINK REF="STD-Adeboyeku-2011" TYPE="STUDY">Adeboyeku 2011</LINK>; <LINK REF="STD-Al_x002d_Ansari-2006" TYPE="STUDY">Al-Ansari 2006</LINK>; <LINK REF="STD-Aminimanizani-2002" TYPE="STUDY">Aminimanizani 2002</LINK>; <LINK REF="STD-Beringer-2012" TYPE="STUDY">Beringer 2012</LINK>; <LINK REF="STD-Conway-1997" TYPE="STUDY">Conway 1997</LINK>; <LINK REF="STD-Hubert-2009" TYPE="STUDY">Hubert 2009</LINK>; <LINK REF="STD-Keel-2011" TYPE="STUDY">Keel 2011</LINK>; <LINK REF="STD-McCabe-2013" TYPE="STUDY">McCabe 2013</LINK>; <LINK REF="STD-Prayle-2013" TYPE="STUDY">Prayle 2013</LINK>; <LINK REF="STD-Noah-2010" TYPE="STUDY">Noah 2010</LINK>; <LINK REF="STD-Riethmueller-2009" TYPE="STUDY">Riethmueller 2009</LINK>; <LINK REF="STD-Semykin-2010" TYPE="STUDY">Semykin 2010</LINK>; <LINK REF="STD-Turner-2013" TYPE="STUDY">Turner 2013</LINK>; <LINK REF="STD-Whitehead-2002" TYPE="STUDY">Whitehead 2002</LINK>). One trial was excluded as it compared two single drugs (<LINK REF="STD-Levy-1982" TYPE="STUDY">Levy 1982</LINK>) and another trial as it compared two different combinations of antibiotics (<LINK REF="STD-Blumer-2005" TYPE="STUDY">Blumer 2005</LINK>). One trial compared intravenous antibiotics administered in hospital compared to at home (<LINK REF="STD-Donati-1987" TYPE="STUDY">Donati 1987</LINK>) and another trial looked at an eradication regimen (<LINK REF="STD-Kenny-2009" TYPE="STUDY">Kenny 2009</LINK>). Five further trials were excluded as allocation was not by randomisation and because there were marked differences in baseline characteristics between the treatment and comparison groups (<LINK REF="STD-Hoogkamp-1983" TYPE="STUDY">Hoogkamp 1983</LINK>; <LINK REF="STD-Hyatt-1981" TYPE="STUDY">Hyatt 1981</LINK>; <LINK REF="STD-Krause-1979" TYPE="STUDY">Krause 1979</LINK>; <LINK REF="STD-Nelson-1985" TYPE="STUDY">Nelson 1985</LINK>; <LINK REF="STD-Roberts-1993" TYPE="STUDY">Roberts 1993</LINK>). Two trials were excluded as they evaluated tools to assess treatment response (<LINK REF="STD-Hatziagorou-2013" TYPE="STUDY">Hatziagorou 2013</LINK>; <LINK REF="STD-Kuni-1992" TYPE="STUDY">Kuni 1992</LINK>).</P>
<P>One trial included 30 participants. However, 17 of these received more than one course of treatment (<LINK REF="STD-Padoan-1987" TYPE="STUDY">Padoan 1987</LINK>). In total, 40 courses of treatment took place (20 in each intervention group). The trial was cross-over in design; but re-randomisation took place between courses of treatment, resulting in some participants possibly receiving two or more courses of the same treatment, or a mixture of different treatments. Since the number of participants receiving each treatment was unclear, results could not be included in the analysis of this review and therefore the trial was excluded. Individual patient data are being requested from the authors of this trial so that data from this trial may be included in future updates (<LINK REF="STD-Padoan-1987" TYPE="STUDY">Padoan 1987</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-03 15:56:58 +0000" MODIFIED_BY="Nikki Jahnke">
<P>In order to assess the risk of bias in the trials, the methodological quality of each trial was assessed using criteria described by Schulz (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). For each trial the following were assessed: concealment of allocation schedule; generation of allocation sequences; inclusion in the analysis of all randomised participants; and double-blinding.<BR/>
</P>
<ALLOCATION MODIFIED="2008-11-11 14:53:59 +0000" MODIFIED_BY="Nikki Jahnke">
<P>One trial stated that treatment was allocated to participants using a computer-generated randomisation (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>); and one trial was stratified for age and disease severity during randomisation (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>). We assessed these trials as having a low risk of bias. Five trials stated that allocation was randomised, but did not specify the method of generation, so we rated the risk of bias in each of these as unclear (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). One trial used alternation but does not discuss how the first participant was randomised to their treatment group and we assessed this as inadequate, thus having a high risk of bias (<LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>).</P>
<P>Four trials were assessed as adequate, Master stated that the code was only broken on completion of the study (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>); another trial stated they used sequentially numbered envelopes (<LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>); a further trial employed sealed envelopes prepared by pharmacy (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>); and the fourth trial stated central randomisation (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). We judged these trials to have a low risk of bias. We assessed one trial as inadequate, since the investigators used alternate allocation and so we judged this to have a high risk of bias (<LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>). We included this trial as a quasi-randomised trial. In the remaining three trials the method of allocation concealment was unclear and so we judged these to have an unclear risk of bias (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-11-10 13:03:34 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Five of the trials were described as double-blinded (<LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). In each trial, saline was used for the placebo injection. We judged these trials to have a low risk of bias. One trial did not explicitly state that blinding had taken place, but did state that both interventions were given with the same volume and in the same way, so it can be assumed that there was some degree of blinding leading to a low risk of bias (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). Two further trials stated that no blinding had taken place, thus we deemed these to have a potential risk of bias (<LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>); and in the remaining trial it was not clear whether blinding had taken place and we judge this to have an unclear risk of bias (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-11-10 12:53:55 +0000" MODIFIED_BY="Nikki Jahnke">
<P>An intention-to-treat analysis was not stated in any of the included trials. In four, however, there appeared to be no withdrawals (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>). In one trial, seven of the 41 participants did not complete the trial, six from the single therapy group and one from the combination group (reasons given) (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>) and another described reasons why three participants out of a cohort of 20 withdrew (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). One trial published a flow chart showing numbers randomized and included or excluded (with reasons) at each stage in paper (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>). A further trial gave the numbers and reasons for withdrawals in a table (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>).</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-12-01 11:48:29 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Only those primary and secondary outcomes of this review, which were reported within the included studies, are listed below. No trial included follow up for longer than six months.</P>
<SUBSECTION>
<HEADING LEVEL="3">Single compared to combination therapy</HEADING>
<P>Pooling of results was difficult because of missing data, differences in method of expression of the results and missing standard deviations.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1. Clinical improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Effect on lung function</HEADING>
<P>Seven of the eight trials included lung function as an outcome measure. However, there was great variety between the trials in the tests used, the time at measurement and the method of expression of the results.</P>
<P>Although the outcome measure given in our protocol was improvement in spirometric lung function, no trial included these data. Two trials measured mean FEV<SUB>1</SUB> and FVC at the end of the treatment course, expressed as per cent predicted (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). These trials were randomised and gave baseline data, clearly stating that there was no significant difference between the single and combination treatment groups at baseline. We therefore analysed these outcomes.</P>
<P>One trial did compare mean change in FEV<SUB>1</SUB> and FVC, expressed as per cent predicted, but did not include standard deviations (SD) in the results, so we could not include the data (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>). No data were given in a further three trials (<LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>) and one trial expressed the results in terms of a median and range (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>).</P>
<P>There were no significant differences between the single and combination treatment groups in the lung function parameters, which we were able to include.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Effect on clinical scores</HEADING>
<P>Measures of change in clinical status were used in most trials. In all but two, either no data or measure of variance were given. One trial measured mean Schwachman score at the end of treatment (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>). This was a randomised trial with no significant difference between the groups at baseline. There was no significant difference between single and combination groups for this parameter.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Bacteriological improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Effect on sputum bacteriology</HEADING>
<P>One trial reported change in sputum <I>P aeruginosa</I> density in colony forming units per gram (cfu/g) (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). This trial showed a significant decrease in <I>P aeruginosa</I> density in both treatment groups, at the end of treatment, with a greater decrease in the combination group. The mean difference in the mean change in density was -1.60 (95% confidence interval (CI) -9.51 to 6.31), i.e. the mean decrease in <I>P aeruginosa</I> density was 1.6 cfu/g greater in the combination treatment group than for the single treatment group. However, on follow up, the density of <I>P aeruginosa</I> in the sputum was similar in both groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Effect on adverse events</HEADING>
<P>Three trials reported adverse events (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). The most commonly reported were: local erythema at the injection site; generalised rash; fever; renal impairment and proteinuria; auditory impairment; and hypersensitivity reaction, with no differences found between treatment groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2. Clinical improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">c. Hospitalisation</HEADING>
<P>Two trials measured the number of participants readmitted to hospital within given time periods of one month (<LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>) and 80 days (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). Huang found no significant difference between the two groups (<LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>). The results from the Smith trial favoured combination therapy with a Peto odds ratio of 0.30 (95% CI 0.12 to 0.73) (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">d. Effect on time to next course of antibiotics</HEADING>
<P>Only one trial reported the effect on the time to next course of antibiotics (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>). There was no significant difference between the two groups.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Bacteriological improvement</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">a. Effect on inflammatory markers</HEADING>
<P>One trial reported blood or sputum markers of inflammation (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). This trial reported mean white blood cell (WBC) count at the end of the antibiotic course and involved treatment groups with similar baseline characteristics. There was no significant difference between the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">b. Effect on antibiotic resistant strains of P aeruginosa</HEADING>
<P>Six of the eight trials examined sputum for drug sensitivity at the beginning of the trial; five of these defined sensitivity in terms of minimum inhibitory concentration (MIC). One trial found that the disc diffusion method did not identify resistant strains (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). The trials varied in their definitions of resistance, e.g. resistance to tobramycin was defined as MIC greater than 8 &#956;g/ml in one trial (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>) and as MIC greater than 32 &#956;g/ml in another (<LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>). No trial used antibiotic sensitivity in their entry criteria. In one trial, the bacteria were clearly sensitive to the antibiotics used (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). This trial gave mean MIC values at baseline and the end of the treatment course and found no significant change. Parry stated MIC values for all the isolates for ticarcillin and carbenicillin, but did not define antibiotic resistance (<LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>). This trial found that the median MIC value for ticarcillin at the end of treatment was same as the pre-treatment value (3.1 &#956;g/ml). One further trial stated that there was no significant difference between the single and combination groups at the beginning of the treatment period, and that emergence of resistance was not seen with any isolate (<LINK REF="STD-McCarty-1988" TYPE="STUDY">McCarty 1988</LINK>). The two remaining trials gave the number or per cent of bacterial sensitivity, but did not comment on whether the two groups were significantly different at baseline (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Huang-1982" TYPE="STUDY">Huang 1982</LINK>).</P>
<P>In the two trials included in the analysis, the number of participants developing resistant strains of <I>P aeruginosa</I> at baseline, end of treatment and follow up at between two and eight weeks was reported (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>; <LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). For completeness, we have shown each of these analyses on the forest plot, as well as the difference between baseline and follow up in two of the trials. The second trial could not be represented in the latter analysis, as the total numbers of participants changed from baseline to follow up (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>). McLaughlin classified bacteria as resistant to tobramycin if the MIC was greater than 8 &#956;g/ml and to azlocillin if the MIC was greater than 125 &#956;g/ml (<LINK REF="STD-McLauglin-1983" TYPE="STUDY">McLauglin 1983</LINK>). Smith defined resistance to tobramycin if the MIC was greater than 8 &#956;g/ml and for azlocillin, if the MIC was greater than 100 &#956;g/ml (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>).</P>
<P>The result of the analysis showed that the difference between the single and combination therapy groups was not significant at baseline or at the end of the treatment course. At two to eight weeks follow up, both trials individually showed an increase in the number of participants with resistant strains of <I>P aeruginosa</I> with single therapy, but the aggregated results showed that the difference was not significant. However, the aggregation of the studies at follow up included a relatively small number of participants, with a total of 40 participants in each group. Calculation of the difference between the numbers of participants with resistant strains from baseline to two to eight weeks post-treatment also favoured combination treatment, although the difference was not significant.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Symptomatic compared to elective regimen</HEADING>
<P>One trial studied outcomes at the end of an elective course of antibiotics and again after a second course three months later, using a cross-over design (<LINK REF="STD-Pedersen-1986" TYPE="STUDY">Pedersen 1986</LINK>). Results were expressed as median and range in all outcomes and therefore meta-analysis using RevMan within this review was not possible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Beta-lactam versus beta-lactam-aminoglycoside combination compared to aminoglycoside versus beta-lactam-aminoglycoside combination</HEADING>
<P>Insufficient data on outcome measures were given in all of the three comparisons of aminoglycoside with aminoglycoside-beta-lactam combination therapy and therefore meta-analysis using RevMan within this review was not possible (<LINK REF="STD-Costantini-1982" TYPE="STUDY">Costantini 1982</LINK>; <LINK REF="STD-Master-1997" TYPE="STUDY">Master 1997</LINK>; <LINK REF="STD-Parry-1977" TYPE="STUDY">Parry 1977</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-11-23 15:21:38 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Choice of anti-pseudomonal antibiotic and the use of single or combined therapy are controversial areas in the treatment of respiratory infection in cystic fibrosis (CF). Current practice is variable. Advantages of combination therapy include a wider range of modes of action, possible synergy and reduction of resistant organisms; whereas advantages of monotherapy include lower cost and reduction of drug-related toxicity. From the perspective of the individual with CF, the use of a beta-lactam alone offers such advantages as ease of administration and no requirement for blood sampling to measure aminoglycoside levels. Current evidence does not provide a clear answer and, therefore, the use of intravenous (IV) antibiotic therapy in CF requires further evaluation.</P>
<P>This review has found eight trials that examined the effect of single compared to combination IV anti-pseudomonal antibiotic therapy for acute exacerbations in CF. There was considerable heterogeneity amongst these trials, which led to difficulties in performing the review and interpreting the results. We were unable to perform adequate meta-analysis for most outcome measures. The overall results showed that there was no significant difference between monotherapy and combination therapy in terms of clinical outcome measures, such as lung function and symptom scores, or in terms of bacteriological outcomes.</P>
<P>These results should be interpreted with caution. All but two of the included trials were published between 1977 and 1988; these were single-centre trials with flaws in the randomisation process. Furthermore, the sample sizes were too small to have the power to detect a difference between the two groups. Three of the eight trials were not published as full papers. Overall, the methodological quality was poor: only one trial was considered to have adequate randomisation allocation and concealment (<LINK REF="STD-Smith-1999" TYPE="STUDY">Smith 1999</LINK>); only four were double-blinded; and none stated any intention-to-treat analysis. The review raises some interesting methodological issues, including the difficulties of pooling results from a number of small trials that are of poor quality.</P>
<P>The trials were very heterogeneous in terms of design, drugs used, duration of treatment and follow up and outcome measures. The combinations of antibiotics in each trial were different and therefore we aggregated the two groups according to the class of antibiotics: beta-lactams and aminoglycosides. Inconsistencies in expression of results and statistical reporting made meta-analysis impossible in most cases and individual patient data would need to be collected from authors to clarify these issues. It was disappointing that only four trials included data that were possible to analyse. Most of the outcome measures analysed included data from only one or two trials. Due to the small number of trials, it was not possible to examine for effects of trial quality, type of antibiotic or treatment regimen using sensitivity and subgroup analyses.</P>
<P>In our protocol we stated that we would like to compare the differences between adults and children. This was not possible, as no trial looked at children alone. No trial looked specifically at quality of life scores. There were no long-term outcome measures such as the development of resistant bacterial strains or side effects, such as ototoxicity to aminoglycosides. This may be relevant particularly to children, in whom there is emerging evidence of ototoxicity due to chronic use of aminoglycosides (<LINK REF="REF-Katbamna-1998" TYPE="REFERENCE">Katbamna 1998</LINK>; <LINK REF="REF-Mulherin-1991" TYPE="REFERENCE">Mulherin 1991</LINK>). Only four trials stated that they had looked for adverse effects; therefore there may have been side effects that have not been identified. The longest follow up in this systematic review was six months, but the majority of trials did not have any follow up after the acute course of antibiotics. Potential problems with development of drug-resistant bacteria, which may shorten long-term survival, may not be detected in trials of such short duration covered by this review.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-11-23 15:21:44 +0000" MODIFIED_BY="Nikki Jahnke">
<IMPLICATIONS_PRACTICE MODIFIED="2016-11-23 15:21:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>The results of this review, regarding the benefits and risks of single versus combination anti-pseudomonal antibiotic therapy in terms of lung function and clinical outcome in people with CF, are inconclusive. In particular, side effects of treatment have not been investigated to a sufficient level, and therefore it is not possible to conclude from this trial that either treatment choice is safe compared to the other. All the trials included in the review looked at different antibiotics, both as a single anti-pseudomonal agent and in combination therapy and therefore the drug(s) of choice remains uncertain.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-11-23 15:21:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>This systematic review raises important questions regarding the use of antibiotic combinations for acute exacerbations in CF, which need to be answered by further randomised controlled trials. These trials need to be designed to overcome the methodological issues highlighted by this review, such as randomisation allocation, blinding, adequate power and long-term follow up. There is a particular need to compare the effects of single anti-pseudomonal therapy versus a combination of anti-pseudomonal antibiotics in terms of long-term toxicity and the development of drug-resistant organisms. An observational cohort study, co-ordinated through national databases, of centres whose practice is either monotherapy or combination therapy may give useful information on a large number of participants for these outcomes. Results need to be standardised to a consistent method of reporting, for example, mean and SD change in FEV<SUB>1</SUB> and FVC expressed as % predicted in order to validate the pooling of results from multiple trials.</P>
<P>This could be particularly pertinent to children, in view of the emergence of long-term side effects such as ototoxicity with cumulative use of aminoglycoside antibiotics. It would be important to address this issue within a trial.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-05-31 13:45:52 +0100" MODIFIED_BY="Nikki Jahnke">
<P>We would like to thank Dr A. Tan for his previous contributions to this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-09-15 13:05:11 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Dr Heather Elphick has no interests to declare.</P>
<P>Dr Alison Scott has no interests to declare.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-02-22 13:42:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Dr. Anton Tan assisted in the assessment of trial quality and extraction of data up until 2013.</P>
<P>Dr. Heather Elphick performed the updates and acts as guarantor of the review. Dr Alison Scott joined the author team as a co-author from the update in 2016.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-09-17 10:25:39 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Description of the pharmacological properties of the antibiotics used in the studies included in the review (<LINK REF="REF-Kucers-1997" TYPE="REFERENCE">Kucers 1997</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="2">1. Beta-Lactams</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">a. Carbenicillin</HEADING>
<P>Carbenicillin is a semisynthetic penicillin derived from the penicillin nucleus 6 APA and can only be administered parenterally. Its most important feature is its activity against <I>Pseudomonas aeruginosa</I> due to its ability to penetrate the outer cell membrane of the bacteria and is less susceptible than other beta-lactam antibiotics to at least one beta-lactamase produced by <I>Pseudomonas aeruginosa</I>. It is also active against other gram positive and negative aerobic organisms including <I>Staphylococcus aureus</I> and <I>Haemophilus influenzae</I>. Principal side effects include hypersensitivity, drug fever and rarely convulsions and effects on platelet function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">b. Ticarcillin</HEADING>
<P>Ticarcillin is very similar to carbenicillin but is at least twice as active against <I>Pseudomonas aeruginosa</I>. It has now replaced carbenicillin for clinical use. As ticarcillin is used in a lower dosage than carbenicillin, it causes fewer side effects, but can be associated with eosinophilia and urticaria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">c. Piperacillin</HEADING>
<P>Piperacillin and azlocillin are semisynthetic penicillins, referred to as 'newer anti-pseudomonal penicillins' and are considerably more active in vitro than carbenicillin and ticarcillin against <I>Pseudomonas aeruginosa</I> due to their ability to pass through the layers of the cell envelope to reach the enzyme penicillin-binding protein PBP3, which is responsible for septum formation during bacterial growth and cell division. Piperacillin is not however clinically superior and development of resistant strains have been observed. Piperacillin also has activity against <I>Burkholderia cepacia</I>, <I>Haemophilus influenzae</I>, <I>Staphylococcus aureus</I> and other gram negative organisms. Main side effects are similar to those of carbenicillin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">d. Azlocillin</HEADING>
<P>Azlocillin is a ureido-penicillin and is similar to piperacillin in its activity against <I>Pseudomonas aeruginosa</I> and acts synergistically with aminoglycosides. Azlocillin-resistant <I>Pseudomonas aeruginosa</I> strains are uncommon. It has some activity against <I>Haemophilus influenzae</I>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">e. Ceftazidime</HEADING>
<P>Ceftazidime is a third generation cephalosporin, resistant to the usual beta-lactamases of most gram negative bacteria and its activity against <I>Pseudomonas aeruginosa</I> is one of its most important properties. Ceftazidime-resistant strains have been described. Ceftazidime can only be administered parenterally and acts in a similar way to penicillin G on the bacterial cell wall and shows an affinity for PBP3. Ceftazidime has low toxicity with a low incidence of hypersensitivity, eosinophilia and reversible elevations in liver enzymes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. Aminoglycosides</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">a. Gentamicin</HEADING>
<P>Gentamicin is an aminoglycoside antibiotic which has particular activity against gram-negative organisms. Its usefulness has decreased since the mid-1970s because of the emergence of bacterial resistance. Gentamicin inhibits bacterial growth by inhibiting protein synthesis in a manner similar to streptomycin. It probably also interacts with the cell envelope of some gram-negative bacilli such as <I>Pseudomonas aeruginosa</I>, resulting in lysis of the cell. Gentamicin has also been shown to inhibit the activity of the extracellular proteases secreted by <I>Pseudomonas aeruginosa</I>, enzymes which contribute to pathogenicity. The major side effects seen with gentamicin are ototoxicity in the form of both cochlear and vestibular toxicity with high prolonged serum levels of the drug and nephrotoxicity due to damage to the proximal tubules, characterised by excretion of casts, oliguria, proteinuria and elevated urea and creatinine. Other side effects include neuromuscular blockade, hypersensitivity reactions and haematological effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">b. Tobramycin</HEADING>
<P>Tobramycin is an aminoglycoside antibiotic with a similar mode of action to gentamicin but its advantages include greater intrinsic activity against <I>Pseudomonas aeruginosa</I>, activity against some gentamicin-resistant strains and lesser nephrotoxicity and therefore is often used in preference to gentamicin. The efficacy and safety of tobramycin given as a once-daily infusion in cystic fibrosis are currently under evaluation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">c. Sisomycin</HEADING>
<P>Sisomycin is another aminoglycoside with similar antimicrobial spectrum to gentamicin. Sisomycin is more active than gentamicin, but less active than tobramycin against <I>Pseudomonas aeruginosa</I>. It has had limited clinical trials and has been available commercially in Europe but not in the UK, USA or Australia. The toxicity is about the same as that of gentamicin.</P>
</SUBSECTION>
</SUBSECTION>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-12-01 11:51:15 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDIES MODIFIED="2016-05-31 13:38:02 +0100" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2014-04-03 15:10:37 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Costantini-1982" MODIFIED="2014-04-03 15:10:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Costantini 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-08-27 14:15:52 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Costantini D, Padoan R, Brienza A, Lodi G, Assael BM, Giunta A</AU>
<TI>Clinical evaluation of carbenicillin and sisomycin alone or in combination in CF patients with pulmonary exacerbations [abstract]</TI>
<SO>Proceedings of the 11th European Cystic Fibrosis Conference</SO>
<YR>1982</YR>
<PG>227</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:15:52 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:15:52 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI122"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132057"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132056"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1982" MODIFIED="2014-04-03 15:10:26 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Huang 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-08-27 14:16:40 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Huang NN, Palmer J, Braverman S, Keith HH, Schidlow D</AU>
<TI>Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study [abstract]</TI>
<SO>23rd Cystic Fibrosis Club Abstracts; 1982 May 14; Washington DC</SO>
<YR>1982</YR>
<PG>124</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:16:40 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:16:40 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI114"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132059"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Master-1997" MODIFIED="2014-04-03 15:10:37 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Master 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-08-27 14:17:22 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Master V, Martin AJ, Holmes M, Roberts G, Coulthard K</AU>
<TI>Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients [abstract]</TI>
<SO>European Respiratory Journal</SO>
<YR>1997</YR>
<VL>10</VL>
<NO>Suppl 25</NO>
<PG>162s</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:17:22 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:17:22 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI148a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132061"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-27 14:17:39 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Master V, Roberts GW, Coulhard KP, Baghurst PA, Martin A, Roberts ME et al</AU>
<TI>Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2001</YR>
<VL>31</VL>
<NO>5</NO>
<PG>367-76</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:17:39 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:17:39 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI148b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132062"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132060"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCarty-1988" MODIFIED="2013-08-27 14:18:25 +0100" MODIFIED_BY="Nikki Jahnke" NAME="McCarty 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-08-27 14:18:25 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W et al</AU>
<TI>Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1988</YR>
<VL>4</VL>
<NO>4</NO>
<PG>201-4</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:18:18 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:18:18 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI58"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132064"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLauglin-1983" MODIFIED="2013-08-27 14:19:47 +0100" MODIFIED_BY="Nikki Jahnke" NAME="McLauglin 1983" YEAR="1983">
<REFERENCE MODIFIED="2013-08-27 14:19:10 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Goldmann DA</AU>
<TI>Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>11 Suppl B</VL>
<PG>195-203</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:19:10 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:19:10 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI26a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132066"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-27 14:19:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McLaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P et al</AU>
<TI>Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>147</VL>
<NO>3</NO>
<PG>559-66</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:19:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:19:47 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI26b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parry-1977" MODIFIED="2013-08-27 14:20:20 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Parry 1977" YEAR="1977">
<REFERENCE MODIFIED="2013-08-27 14:20:20 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR</AU>
<TI>Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin</TI>
<SO>Journal of Pediatrics</SO>
<YR>1977</YR>
<VL>90</VL>
<NO>1</NO>
<PG>144-8</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:20:20 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:20:20 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI17"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132069"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132068"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1986" MODIFIED="2013-08-27 14:20:56 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Pedersen 1986" YEAR="1986">
<REFERENCE MODIFIED="2013-08-27 14:20:56 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis-Moller A, Kock C</AU>
<TI>Immediate and prolonged clinical efficacy of Ceftazidime versus Ceftazidime plus Tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1986</YR>
<VL>18</VL>
<PG>133-7</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:20:56 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:20:56 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Registere" TYPE="OTHER" VALUE="PI42"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132070"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1999" MODIFIED="2013-08-27 14:21:47 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Smith 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-08-27 14:21:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M et al</AU>
<TI>Comparison of a B-lactam alone versus B-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1999</YR>
<VL>134</VL>
<NO>4</NO>
<PG>413-21</PG>
<IDENTIFIERS MODIFIED="2013-08-27 14:21:47 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 14:21:47 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI152"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132073"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132072"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-05-31 13:38:02 +0100" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Adeboyeku-2011" MODIFIED="2011-11-02 21:08:14 +0000" MODIFIED_BY="[Empty name]" NAME="Adeboyeku 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-11-02 21:08:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adeboyeku D, Jones AL, Hodson ME</AU>
<TI>Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI243"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132075"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Ansari-2006" MODIFIED="2014-04-03 14:11:41 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Al-Ansari 2006" YEAR="2001">
<REFERENCE MODIFIED="2014-04-03 14:11:10 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al Ansari NA, Foweraker J, Mackeown D, Bilton D</AU>
<TI>Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients [abstract]</TI>
<SO>Qatar Medical Journal</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>1</NO>
<PG>34-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI173b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132077"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-02 21:08:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Ansari N, McKeon D, Parmer J, Gunn E, Foweraker J, Bilton D</AU>
<TI>Efficacy of once daily tobramycin for acute pulmonary exacerbations of cystic fibrosis (CF) - a microbiological perspective [abstract]</TI>
<SO>Thorax</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>Suppl 3</NO>
<PG>iii85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI173a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132078"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aminimanizani-2002" MODIFIED="2014-04-03 14:13:32 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Aminimanizani 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-02 21:09:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ</AU>
<TI>Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2002</YR>
<VL>50</VL>
<NO>4</NO>
<PG>553-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI158b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:13:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsang L, Aminimanizani A, Beringer PM, Jelliffe R, Shapiro B</AU>
<TI>Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>Suppl 20</NO>
<PG>284</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI158a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132079"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balsamo-1986" MODIFIED="2014-04-03 14:16:44 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Balsamo 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-04-03 14:16:30 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Balsamo V, Bragion E, Iapichino L, Natozi D, Pardo F</AU>
<TI>Clinical efficacy and "in vitro" activity of some antibiotics, ceftazidime aztreonam or carbenicillin with aminoglycosides against Pseudomonas in Cystic fibrosis patients [abstract]</TI>
<SO>14th Annual Meeting of the European Working Group for Cystic Fibrosis</SO>
<YR>1986</YR>
<PG>63</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:16:30 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:16:30 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI84"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beaudry-1980" MODIFIED="2014-04-03 14:19:19 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Beaudry 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-04-03 14:19:11 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R</AU>
<TI>Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?</TI>
<SO>Journal of Pediatrics</SO>
<YR>1980</YR>
<VL>97</VL>
<NO>1</NO>
<PG>144-7</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:19:11 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:19:11 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI21a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132085"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:19:19 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Beaudry PH, Marks MI, Rangel R, McDougall D, Desmond K</AU>
<TI>Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? [abstract]</TI>
<SO>20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia</SO>
<YR>1979</YR>
<PG>1</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:19:19 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:19:19 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI21b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132086"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beringer-2012" MODIFIED="2014-04-02 15:18:30 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Beringer 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-04-02 15:18:18 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beringer P, Owens H, Nguyen A, Benitez D, Boyd-King A, Rao AP</AU>
<TI>Safety, pharmacokinetics and preliminary evaluation of the antiinflammatory effect of doxycycline in CF [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45 Suppl 33</VL>
<PG>370, Abstract no: 422</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI256a"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011256"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132088"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-02 15:18:30 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ</AU>
<TI>Pharmacokinetics of doxycycline in adults with cystic fibrosis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>1</NO>
<PG>70-4</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI256b"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011269"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132087"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumer-2005" MODIFIED="2016-02-22 13:01:57 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Blumer 2005" YEAR="2003">
<REFERENCE MODIFIED="2016-02-22 13:01:51 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Blumer JL, Minkwitz M, Saiman L, San Gabriel P, Iaconis J, Melnick D</AU>
<TI>Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with <I>Pseudomonas aeruginosa</I> (PA) or <I>Burkholderia cepacia</I> (BC) [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>Suppl 25</VL>
<PG>294</PG>
<IDENTIFIERS MODIFIED="2016-02-22 13:01:38 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2016-02-22 13:01:38 +0000" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI179a"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000002583"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132091"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-22 13:01:46 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumer JL, Saiman L, Konstan MW, Melnick D</AU>
<TI>The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis</TI>
<SO>Chest</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>4</NO>
<PG>2336-46</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="531312"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI179b"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500100000006414"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132092"/><IDENTIFIER TYPE="PUBMED" VALUE="16236892"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bosso-1988" MODIFIED="2014-04-03 14:22:25 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Bosso 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-04-03 14:22:19 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosso JA, Black PG</AU>
<TI>A comparative trial of aztreonam and tobramycin plus azlocillin [abstract]</TI>
<SO>Excerpta medica, Asia Pacific Congress Series</SO>
<YR>1988</YR>
<VL>74</VL>
<PG>R(c)17</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:22:19 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:22:19 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI59a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132094"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:22:25 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bosso JA, Black PG</AU>
<TI>Controlled trial of aztreonam vs tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1988</YR>
<VL>7</VL>
<NO>3</NO>
<PG>171-6</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:20:05 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:20:05 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI59b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132093"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Church-1997" MODIFIED="2014-04-03 14:23:20 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Church 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-03 14:23:20 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, et al</AU>
<TI>Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1997</YR>
<VL>16</VL>
<NO>1</NO>
<PG>97-105</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:23:20 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:23:20 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI115"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conway-1997" MODIFIED="2014-04-03 14:25:23 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Conway 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-04-03 14:24:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Conway SP, Pond M, Watson A , Etherington C, Robey HL, Goldman MH</AU>
<TI>Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis</TI>
<SO>Thorax</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>11</NO>
<PG>987-93</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:24:32 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:24:32 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI103c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132099"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:25:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Conway SP, Pond M, Watson A, Robey H, Goldman M</AU>
<TI>A safety profile of intravenous colomycin in adult care [abstract]</TI>
<SO>20th European Cystic Fibrosis; 1995 June 18-21; Brussels, Belgium</SO>
<YR>1995</YR>
<PG>P3</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:25:05 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:25:05 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI103a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132100"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:25:23 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Conway SP, Pond MN, Watson AJ, Robey H, Goldman MH</AU>
<TI>Colistin alone or in combination with a second antibiotic is effective in the treatment of respiratory exacerbations in cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1996</YR>
<VL>Suppl 13</VL>
<PG>296</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:25:23 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:25:23 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI103b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boeck-1989" MODIFIED="2014-04-03 14:26:41 +0100" MODIFIED_BY="Nikki Jahnke" NAME="De Boeck 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-04-03 14:26:41 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Boeck K, Smet M, Eggermont E</AU>
<TI>Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1989</YR>
<VL>7</VL>
<NO>3</NO>
<PG>171-3</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:26:41 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:26:41 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI61"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boeck-1999" MODIFIED="2014-04-03 14:27:32 +0100" MODIFIED_BY="Nikki Jahnke" NAME="De Boeck 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-04-03 14:27:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Boeck K, Sauer K, Vandeputte S</AU>
<TI>Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients [abstract]</TI>
<SO>The Netherlands Journal of Medicine</SO>
<YR>1999</YR>
<VL>54</VL>
<PG>S39</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:27:32 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:27:32 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI150"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donati-1987" MODIFIED="2011-11-02 21:10:33 +0000" MODIFIED_BY="[Empty name]" NAME="Donati 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-11-02 21:10:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donati MA, Guenette G, Auerbach H</AU>
<TI>Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease</TI>
<SO>Journal of Pediatrics</SO>
<YR>1987</YR>
<VL>111</VL>
<NO>1</NO>
<PG>28-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI143"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132107"/><IDENTIFIER TYPE="MEDLINE" VALUE="87253633"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gold-1985" MODIFIED="2014-04-03 14:31:40 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Gold 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-03 14:31:40 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold R, Overmeyer A, Knie B, Fleming PC, Levison H</AU>
<TI>Controlled trial of ceftazidime vs ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>1985</YR>
<VL>4</VL>
<NO>2</NO>
<PG>172-7</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:31:40 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:31:40 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI35"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132109"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hatziagorou-2013" MODIFIED="2014-04-02 15:15:42 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hatziagorou 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-04-02 15:15:42 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J</AU>
<TI>Lung clearance index: a tool to assess the response to intravenous treatment among children with cystic fibrosis [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2013</YR>
<VL>12 Suppl 1</VL>
<PG>S26, Abstract no: WS13.3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI265"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011544"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132111"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132110"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoogkamp-1983" MODIFIED="2014-04-03 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hoogkamp 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-04-03 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoogkamp-Korstanje JA, van der Laag J</AU>
<TI>Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>2</NO>
<PG>175-83</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:33:55 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI140"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132113"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132112"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hubert-2009" MODIFIED="2014-04-03 14:37:36 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hubert 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-03 14:37:36 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al</AU>
<TI>Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2009</YR>
<VL>53</VL>
<NO>9</NO>
<PG>3650-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI180b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132115"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:37:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hubert D, Wallaert B, Scheid P, Ramel S, Grenet D, Sermet-Gaudelus I, et al</AU>
<TI>Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2003</YR>
<VL>Suppl 25</VL>
<PG>294</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:37:31 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:37:31 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI180a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132114"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hyatt-1981" MODIFIED="2014-04-03 14:38:33 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Hyatt 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-04-03 14:38:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hyatt AC, Chipps BE, Kumor KM, Mellits ED, Lietman PS, Rosenstein BJ</AU>
<TI>A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1981</YR>
<VL>99</VL>
<NO>2</NO>
<PG>307-11</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:38:33 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:38:33 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI23"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132118"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132117"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jewett--1985" MODIFIED="2014-04-03 14:39:11 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Jewett  1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-03 14:39:11 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jewett CV, Ledbetter J, Lyrene RK, Brasfield DM, Tiller RE</AU>
<TI>Comparison of cefoperazone sodium vs methicillin, ticarcillin and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>106</VL>
<NO>4</NO>
<PG>669-72</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:39:11 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:39:11 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI36"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132120"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132119"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keel-2011" MODIFIED="2014-04-02 15:24:13 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Keel 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-04-02 15:24:13 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al</AU>
<TI>Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2011</YR>
<VL>55</VL>
<NO>7</NO>
<PG>3393-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI251"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000005261"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132121"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenny-2009" MODIFIED="2011-11-02 21:10:13 +0000" MODIFIED_BY="[Empty name]" NAME="Kenny 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-02 21:10:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenny S, Hall V, Goldsmith C, Moore J, Rendall JC, Elborn JS</AU>
<TI>Eradication of Pseudomonas aeruginosa in adults with CF [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>Suppl 2</NO>
<PG>S39, Abstract no: 158</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI229"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132124"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132123"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krause-1979" MODIFIED="2014-04-03 14:40:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Krause 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-04-03 14:40:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krause PJ, Young LS, Cherry JD, Osher AB, Spencer MJ, Bryson YJ</AU>
<TI>The treatment of exacerbations of pulmonary disease in cystic fibrosis: netilmicin compared with netilmicin and carbenicillin</TI>
<SO>Current Therapeutic Research Clinical and Experimental</SO>
<YR>1979</YR>
<VL>25</VL>
<PG>609</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:40:02 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:40:02 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI166"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132126"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132125"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuni-1992" MODIFIED="2011-11-02 21:10:47 +0000" MODIFIED_BY="[Empty name]" NAME="Kuni 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-11-02 21:10:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuni CC, Regelmann WE, duCret RP, Boudreau RJ, Budd JR</AU>
<TI>Aerosol scintigraphy in the assessment of therapy for cystic fibrosis</TI>
<SO>Clinical Nuclear Medicine</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>2</NO>
<PG>90-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI236"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132128"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132127"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1982" MODIFIED="2014-04-03 14:40:54 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Levy 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-04-03 14:40:54 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy J, Baran D, Klastersky J</AU>
<TI>Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>3</NO>
<PG>227-34</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:40:54 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:40:54 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI134"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132130"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132129"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCabe-2013" MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="McCabe 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCabe D, Rodgers HC</AU>
<TI>Evaluation of a twice daily tobramycin regimen in adult cystic fibrosis patients [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2013</YR>
<VL>12 Suppl 1</VL>
<PG>S71, Abstract no: 89</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI266"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000011543"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132132"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132131"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nelson-1985" MODIFIED="2014-04-03 15:20:45 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Nelson 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-03 15:20:45 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD</AU>
<TI>Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis</TI>
<SO>Pediatric Infectious Disease</SO>
<YR>1986</YR>
<VL>5</VL>
<NO>4</NO>
<PG>440-3</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:42:09 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:42:09 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI38b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132134"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:42:33 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nelson JD</AU>
<TI>Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal</TI>
<SO>Journal of Pediatrics</SO>
<YR>1985</YR>
<VL>106</VL>
<PG>1030-4</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:42:33 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:42:33 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI38a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132133"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noah-2010" MODIFIED="2014-04-03 14:45:23 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Noah 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 14:45:13 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noah T, Ivins S, Abode K, Harris W, Henry M, Leigh M</AU>
<TI>Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2007</YR>
<VL>42 Suppl 30</VL>
<PG>332</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:45:13 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:45:13 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI205a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132137"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:45:23 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, et al</AU>
<TI>Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2010</YR>
<VL>45</VL>
<NO>3</NO>
<PG>281-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI205b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132138"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132136"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Padoan-1987" MODIFIED="2014-04-03 14:46:41 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Padoan 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-04-03 14:46:09 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Padoan R, Cambisano W, Constantini D, Crossignani R, Giunta A</AU>
<TI>Pseudomonas pulmonary infections in cystic fibrosis: Ceftazidime vs ceftazidime plus sisomicin vs piperacillin plus sisomicin [abstract]</TI>
<SO>9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England</SO>
<YR>1984</YR>
<PG>Poster 4.21</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:46:09 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:46:09 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI52a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132140"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:46:41 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G et al</AU>
<TI>Ceftazidime monotherapy vs combined therapy in Pseudomonas pulmonary infections in cystic fibrosis</TI>
<SO>Pediatric Infectious Diseases Journal</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>7</NO>
<PG>648-53</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:46:41 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:46:41 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI52b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132139"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Permin-1983" MODIFIED="2014-04-03 14:47:32 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Permin 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-04-03 14:47:32 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, Moller S</AU>
<TI>Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1983</YR>
<VL>12</VL>
<NO>Suppl A</NO>
<PG>313-23</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:47:32 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:47:32 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI29"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132143"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132142"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prayle-2013" MODIFIED="2016-05-31 13:37:57 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Prayle 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-31 13:37:57 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prayle A, Jain K, Watson A, Smyth AR</AU>
<TI>Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2013</YR>
<VL>48 Suppl 36</VL>
<PG>299, Abstract no: 261</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="980338"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="CO55"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000420"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4479405"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4479404"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riethmueller-2009" MODIFIED="2014-04-03 14:57:41 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Riethmueller 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-04-03 14:47:53 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al</AU>
<TI>Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients</TI>
<SO>Infection</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>5</NO>
<PG>424-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154f"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132145"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:52:36 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riethmueller J, Busch A, Franke P, Ziebach R, von Butler R, Stern M</AU>
<TI>Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract]</TI>
<SO>13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden</SO>
<YR>2000</YR>
<PG>166</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:50:34 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:50:34 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132146"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:57:41 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al</AU>
<TI>Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract]</TI>
<SO>24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria</SO>
<YR>2001</YR>
<PG>P192</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:52:11 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:52:11 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132147"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-02 21:11:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al</AU>
<TI>Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis</TI>
<SO>Infection</SO>
<YR>2009</YR>
<VL>37</VL>
<NO>5</NO>
<PG>418-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154e"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132148"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:55:05 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schroeter T, Eggert P, Riethmueller J, Stern M, Claass A</AU>
<TI>Acute-phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once-versus thrice-daily dosing [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2002</YR>
<VL>Suppl 24</VL>
<PG>289</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:55:05 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:55:05 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154d"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132149"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 14:57:16 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schroeter TW, Eggert P, Riethmueller J, Stern M, Claass A</AU>
<TI>A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract]</TI>
<SO>24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria</SO>
<YR>2001</YR>
<PG>P190</PG>
<IDENTIFIERS MODIFIED="2014-04-03 14:57:16 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 14:57:16 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI154c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132144"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1993" MODIFIED="2014-04-03 15:03:06 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Roberts 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-04-03 15:02:37 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roberts GW, Nation RL, Jarvinen AO, Martin AJ</AU>
<TI>An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1993</YR>
<VL>36</VL>
<NO>4</NO>
<PG>372-5</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:02:37 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 15:02:37 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI132a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132152"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:03:06 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts GW, Nation RL, Jarvinen AO</AU>
<TI>Measurement of serum tobramycin in the presence of ticarcillin or piperacillin</TI>
<SO>Australian Journal of Hospital Pharmacy</SO>
<YR>1992</YR>
<VL>22</VL>
<NO>2</NO>
<PG>152-4</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:03:06 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 15:03:06 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI132b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Semykin-2010" MODIFIED="2014-04-03 13:40:16 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Semykin 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-04-03 13:40:16 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Semykin SY, Polikarpova SV, Dubovik LG, Kashirskaya NY</AU>
<TI>Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]</TI>
<SO>Journal of Cystic Fibrosis</SO>
<YR>2010</YR>
<VL>9 Suppl 1</VL>
<PG>S55, Abstract no: 214</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI246"/><IDENTIFIER OTHERTYPE="CRS-ID" TYPE="OTHER" VALUE="5500100000005273"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stack-1985" MODIFIED="2014-04-03 15:07:14 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Stack 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-04-03 15:07:14 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>British Thoracic Society Research Committee</AU>
<TI>Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms</TI>
<SO>Thorax</SO>
<YR>1985</YR>
<VL>40</VL>
<NO>5</NO>
<PG>358-63</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:07:14 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 15:07:14 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI37a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132157"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:06:31 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Stack BHR, Geddes DM, Williams KJ, Dinwiddie R, Selkon JB, Godfrey RC</AU>
<TI>Ceftazidime compared with a combination of gentamicin and carbenicillin in cystic fibrosis patients with persistent pulmonary pseudomonas infection and an acute exacerbation of respiratory symptoms [abstract]</TI>
<SO>9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England</SO>
<YR>1984</YR>
<PG>4.16</PG>
<IDENTIFIERS MODIFIED="2014-04-03 15:06:31 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2014-04-03 15:06:31 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI37b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132158"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132156"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turner-2013" MODIFIED="2016-05-31 13:38:02 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Turner 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-05-31 13:38:02 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turner R, Biondo LR, Slain D, Phillips U, Cardenas SC, Moffett K</AU>
<TI>A randomized pilot study of continuous versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>2013</YR>
<VL>48 Suppl 36</VL>
<PG>326, Abstract no: 332</PG>
<IDENTIFIERS><IDENTIFIER TYPE="CENTRAL" VALUE="980337"/><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI272"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500125000000418"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4479407"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4479406"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wesley-1988" NAME="Wesley 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wesley AW, Quested C, Edgar BW, Lennon DR</AU>
<TI>A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of pseudomonas chest infection in children with cystic fibrosis [abstract]</TI>
<SO>Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney, Australia. (Excerpta Medica, Asia Pacific Congress Series, No. 74)</SO>
<YR>1988</YR>
<PG>13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132159"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitehead-2002" MODIFIED="2014-04-03 15:08:10 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Whitehead 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-04-03 15:07:52 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watson A, Whitehead A, Conway SP, Etherington C</AU>
<TI>Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>19</NO>
<PG>262-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI149b"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:08:10 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S</AU>
<TI>Once-daily tobramycin in the treatment of adult patients with cystic fibrosis</TI>
<SO>European Respiratory Journal</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>2</NO>
<PG>303-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI149c"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132163"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-04-03 15:07:47 +0100" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitehead A, Conway SP, Etherington C, Dave J</AU>
<TI>Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]</TI>
<SO>The Netherlands Journal of Medicine</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>Suppl</NO>
<PG>S36-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI149a"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3132164"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3132161"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-10-27 09:33:04 +0100" MODIFIED_BY="Nikki Jahnke">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Cantin-1995" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Cantin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cantin A</AU>
<TI>Cystic fibrosis lung inflammation: early, sustained and severe</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>4</NO>
<PG>939-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheng-1996" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Cheng 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al</AU>
<TI>Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9028</NO>
<PG>639-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frederiksen-1999" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Frederiksen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Frederiksen B, Koch C, Hoiby N</AU>
<TI>Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>3</NO>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoiby-1993" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Hoiby 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hoiby N</AU>
<TI>Antibiotic therapy for chronic infection of pseudomonas in the lung</TI>
<SO>Annual Review of Medicine</SO>
<YR>1993</YR>
<VL>44</VL>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katbamna-1998" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Katbamna 1998" TYPE="JOURNAL_ARTICLE">
<AU>Katbamna B, Homnick DN, Marks JH</AU>
<TI>Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: effects of tobramycin</TI>
<SO>Journal of the American Academy of Audiology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>3</NO>
<PG>172-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstan-1997" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Konstan 1997" TYPE="JOURNAL_ARTICLE">
<AU>Konstan MW, Berger M</AU>
<TI>Current understanding of the inflammatory process in cystic fibrosis: onset and etiology</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>2</NO>
<PG>137-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kucers-1997" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Kucers 1997" TYPE="BOOK">
<AU>Kucers A, Crowe S, Grayson M, Hoy J (editors)</AU>
<SO>The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs</SO>
<YR>1997</YR>
<EN>5th</EN>
<PB>Hodder Arnold</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-17 10:23:40 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2008-09-17 10:23:40 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="OTHER" VALUE="ISBN-10: 0750601558 "/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Levy-1998" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Levy 1998" TYPE="JOURNAL_ARTICLE">
<AU>Levy SB</AU>
<TI>Antimicrobial resistance: bacteria on the defence. Resistance stems from misguided efforts to try to sterilise our environment</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7159</NO>
<PG>612-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulherin-1991" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Mulherin 1991" TYPE="JOURNAL_ARTICLE">
<AU>Mulherin D, Fahy J, Grant W, Keogan M, Kavanagh B, FitzGerald M</AU>
<TI>Aminoglycoside induced ototoxicity in patients with cystic fibrosis</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1991</YR>
<VL>160</VL>
<NO>6</NO>
<PG>173-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regelmann-1990" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Regelmann 1990" TYPE="JOURNAL_ARTICLE">
<AU>Regelmann WE, Elliott GR, Warwick WJ, Clawson CC</AU>
<TI>Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1990</YR>
<VL>141</VL>
<NO>4 Pt 1</NO>
<PG>914-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical Evidence of Bias</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2002" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Tan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Tan KH, Hyman-Taylor P, Mulheran M, Knox A, Smyth A</AU>
<TI>Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers</TI>
<SO>Paediatric Pulmonology</SO>
<YR>2002</YR>
<VL>33</VL>
<NO>2</NO>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1993" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Taylor 1993" TYPE="JOURNAL_ARTICLE">
<AU>Taylor RF, Hodson ME</AU>
<TI>Cystic Fibrosis: antibiotic prescribing practices in the United Kingdom and Eire</TI>
<SO>Respiratory Medicine</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>7</NO>
<PG>535-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolter-1999" MODIFIED="2008-11-11 14:42:53 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Wolter 1999" TYPE="JOURNAL_ARTICLE">
<AU>Wolter JM, Bowler SD, McCormack JG</AU>
<TI>Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>1</NO>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-02-22 13:54:00 +0000" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Elphick-2002" NAME="Elphick 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elphick HE, Tan A, Ashby D, Smyth RL</AU>
<TI>Systematic reviews and lifelong diseases</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<NO>7360</NO>
<PG>381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elphick-2005" MODIFIED="2013-08-27 15:47:15 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Elphick 2005" TYPE="COCHRANE_REVIEW">
<AU>Elphick HE, Tan AA</AU>
<TI>Single versus combination intravenous antibiotic therapy for people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2013-08-27 15:47:15 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2013-08-27 15:47:15 +0100" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002007.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Elphick-2014" MODIFIED="2016-02-22 13:54:00 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Elphick 2014" TYPE="COCHRANE_REVIEW">
<AU>Elphick HE, Jahnke N</AU>
<TI>Single versus combination intravenous antibiotic therapy for people with cystic fibrosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2016-02-22 13:54:00 +0000" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER MODIFIED="2016-02-22 13:54:00 +0000" MODIFIED_BY="Nikki Jahnke" TYPE="DOI" VALUE="10.1002/14651858.CD002007.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-10-27 09:33:04 +0100" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Al_x002d_Aloul-2004" MODIFIED="2016-10-27 09:33:04 +0100" MODIFIED_BY="Nikki Jahnke" NAME="Al-Aloul 2004" TYPE="JOURNAL_ARTICLE">
<AU>Al-Aloul M, Miller H, Ledson MJ, Walshaw MJ</AU>
<TI>Tobramycin nebuliser solution (TOBI): a renal sparing alternative to intravenous (IV) tobramycin in acute pulmonary exacerbations in CF [Abstract]</TI>
<SO>Thorax</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>Suppl II</NO>
<PG>ii79</PG>
<IDENTIFIERS MODIFIED="2016-10-27 09:33:04 +0100" MODIFIED_BY="Nikki Jahnke"><IDENTIFIER TYPE="CENTRAL" VALUE="517107"/><IDENTIFIER MODIFIED="2016-10-27 09:33:04 +0100" MODIFIED_BY="Nikki Jahnke" OTHERTYPE="CFGD Register" TYPE="OTHER" VALUE="PI186d"/><IDENTIFIER OTHERTYPE="CRS" TYPE="OTHER" VALUE="5500050000000402"/></IDENTIFIERS>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-05-31 13:40:05 +0100" MODIFIED_BY="Nikki Jahnke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-03 15:57:36 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Costantini-1982">
<CHAR_METHODS>
<P>No withdrawals, symptomatic regimen.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>28 participants randomised. PsA colonised, age not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Carbenicillin 675 mg/kg/day vs sisomycin 10.5 mg/kg/day vs carbenicillin 590 mg/kg/day plus sisomycin. Variable duration of course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>CXR and symptom scores, bacteriology, development of resistant strains.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract: no data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 14:54:54 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Huang-1982">
<CHAR_METHODS MODIFIED="2008-11-10 14:54:54 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind trial, no withdrawals, symptomatic regimen. Parallel trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16 participants randomised. Mixed PsA and non-PsA, age not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ticarcillin 300 mg/kg/day vs ticarcillin plus tobramycin 6 mg/kg/day. 10-day course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, number readmitted within one month, CXR and symptom scores, bacteriology.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract: Lung function, CXR and symptom score data not given.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 14:56:00 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Master-1997">
<CHAR_METHODS MODIFIED="2008-11-10 14:55:19 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind trial, symptomatic regimen. Parallel trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 14:56:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>83 participants randomised. PsA colonised, age not stated.</P>
<P>51 participants randomized, of these, 21 in the tobramycin and ceftazidime group (51 admissions assessed) and 23 in the tobramycin group (47 admissions assessed). 12 participants in the tobramycin and ceftazidime group and 9 participants in the tobramycin group were eligible for long-term assessment. Participants in both groups experienced an average of 3.1 and 3.0 admissions, respectively, for IV antibiotic treatment during the study period.</P>
<P>Tobramycin and ceftazidime group: mean (SD) age 16 (7) years<BR/>Tobramycin group: mean (SD) age 14 (5) years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Tobramycin 24-hourly vs tobramycin and ceftazidime 8-hourly. 10-day course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-11 14:56:00 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Full paper. Exclusion criteria stated.</P>
<P>The study was halted for a period of 3 months when<BR/>one of the study patients committed suicide by utilizing a<BR/>study syringe to administer a lethal substance. The study<BR/>was recommenced after the coroner's finding that this<BR/>was an unrelated death. During this time of study suspension,<BR/>there were 14 admissions of patients previously<BR/>enrolled. Data from these admissions were not included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-11 14:56:49 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-McCarty-1988">
<CHAR_METHODS>
<P>Not double blind, no withdrawals, symptomatic regimen.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-11 14:56:49 +0000" MODIFIED_BY="Nikki Jahnke">
<P>17 participants treated (8 in piperacillin group, 9 in piperacillin plus tobramycin group); 3 participants treated on more than one occasion (2 initially in piperacillin group and several months later randomised to other group; 1 participant enrolled 2x in piperacillin group). 20 data sets. Mixed PsA and non-PsA, aged 2 to 12 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Piperacillin 600 mg/kg/day vs piperacillin plus tobramycin 8 to 10 mg/kg/day, minimum duration 10 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, weight, symptom scores, adverse events, bacteriology.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data for lung function, weight and symptom scores.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 14:58:44 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-McLauglin-1983">
<CHAR_METHODS>
<P>Double-blind trial, symptomatic regimen.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 14:57:52 +0000" MODIFIED_BY="Nikki Jahnke">
<P>41 participants randomised (11 years and older), 34 completed. No ITT analysis. Mean age 21 years. PsA in 98%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-10 14:58:41 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Azlocillin 300 mg/kg/day, 4-hourly plus placebo vs azlocillin plus tobramycin 6 mg/kg/day, 8-hourly. 10-day course.</P>
<P>Group 1: azlocillin 300 mg/kg/day in 6 divided doses plus tobramycin (6 mg/kg per day) in 3 divided doses.<BR/>Group 2:azlocillin 300 mg/kg/day in 6 divided doses plus placebo (0.85% NaCl) in 3 divided doses.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 14:58:42 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Lung function, symptom scores, development of resistant strains, time to next course.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-10 14:58:44 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Participants were white, of various socioeconomic backgrounds and lived in New England. Exclusion criteria stated.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 14:59:45 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Parry-1977">
<CHAR_METHODS MODIFIED="2008-11-10 14:59:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Not double blind, alternate allocation, no withdrawals, symptomatic regimen. Parallel trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 14:59:34 +0000" MODIFIED_BY="Nikki Jahnke">
<P>21 male, 21 female, mean age 15.1 years. PsA colonised.</P>
<P>14 participants in each of 3 treatment groups.<BR/>Group 1 (ticarcillin): 8 male, 6 female; mean (range) age 16.1 (2 - 30) years<BR/>Group 2 (ticarcillin &amp; gentamicin): 7 males, 7 females: mean (range) age 16.4 (4 - 30) years<BR/>Group 3 (gentamicin):6 males, 8 females; mean (range) 12.9 (5 - 31) years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ticarcillin 300 mg/kg/day, 4-hourly vs gentamicin 3 - 4 mg/kg/day (adults), 4 - 7 mg/kg/day (children) vs combination. Variable length of course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-10 14:59:45 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Lung function, bacteriology, adverse events, CBC, sedimentation rate, urinalysis, serum electrolytes, blood urea nitrogen, creatinine, liver function tests, chest radiographs, blood gas determinations, sputum cultures, change in cough, weight.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:00:27 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Pedersen-1986">
<CHAR_METHODS MODIFIED="2008-11-10 15:00:15 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Not double blind, elective regimen,<BR/>crossover - 3 months in between treatment arms.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:00:27 +0000" MODIFIED_BY="Nikki Jahnke">
<P>20 participants (10 male, 10 female), mean age 12.6 years. PsA colonised. 3 drop outs, 17 completed trial.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ceftazidime 150 mg/kg/day, 8-hourly vs ceftazidime plus tobramycin 10 mg/kg/day, 8-hourly, 14-day course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, inflammatory markers, development of resistant strains.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-10 15:02:59 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Smith-1999">
<CHAR_METHODS MODIFIED="2008-11-10 15:02:16 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Double-blind, computer-generated randomisation, symptomatic regimen. Parallel trial. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-10 15:02:59 +0000" MODIFIED_BY="Nikki Jahnke">
<P>37 male, 39 female, mean age 16.3 years.<BR/>111 participants enrolled, 35 withdrawn. 76 participants in total aged 6 - 18 years. PsA colonised.</P>
<P>Group 1 (azlocillin): 33 participants (19 male) mean (SD) age 16.07 (7.4) years<BR/>Group 2 (azlocillin &amp; tobramycin): 43 participants (18 male) mean (SD) age 16.53 (6.9) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Azlocillin 450 mg/kg/day, 4-hourly plus placebo vs azlocillin plus tobramycin 240 mg/m2/day, 6-hourly, 14 days course.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lung function, time to next admission, symptom scores, adverse events, bacteriology, inflammatory markers, resistant strains.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data for symptom scores.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CBC: complete blood count<BR/>CXR: chest x-ray<BR/>ITT: intention-to-treat<BR/>PsA: <I>Pseudomonas aeruginosa</I>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-05-31 13:40:05 +0100" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:37:53 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Adeboyeku-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:37:53 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of twice daily vs three times daily antibiotics, not single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:37:58 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Al_x002d_Ansari-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:37:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of once vs multiple daily dosing, not single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:06 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Aminimanizani-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:06 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of single vs multiple daily dosing, not single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Balsamo-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beaudry-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:23 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Beringer-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:23 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics; a comparison of a single intravenous dose of an antibiotic and multiple oral doses of the same antibiotic.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 13:46:50 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Blumer-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 13:46:50 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of two combination regimens.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bosso-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-07 13:27:38 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Church-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-07 13:27:38 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Conway-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of colistin with multiple antibiotic combinations.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Boeck-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Boeck-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:26 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Donati-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:26 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Home vs hospital therapy, not single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gold-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:26 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hatziagorou-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:26 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of a single vs combination antibiotics; evaluation of tool to assess treatment response in children.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoogkamp-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised study: first 7 participants allocated to single treatment; next 7 to combination treatment with marked differences in baseline characteristics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:28 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Hubert-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:28 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Comparison of intermittent vs continuous infusions, not single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hyatt-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of anti-staphylococcal drug (oxacillin) vs oxacillin plus 2 anti-pseudomonal drugs.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jewett--1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:29 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Keel-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:29 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of a single vs combination antibiotic; comparison of intravenous and oral versions of the same agent.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:43 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kenny-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:43 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Study of eradication of <I>Pseudomonas aeruginosa</I>, not a comparison of single vs combination.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-09-17 10:27:58 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Krause-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-09-17 10:27:58 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Pseudo-randomised study. Treatment and comparison groups were not sufficiently similar at baseline.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:44 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Kuni-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:44 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levy-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of 2 single agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:45 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-McCabe-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:45 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics; evaluation of a twice-daily tobramycin regimen.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:48 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Nelson-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:48 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Review article on single vs combination antibiotic treatment, i.e. not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:49 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Noah-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Inhaled vs systemic antibiotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Padoan-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reported number of courses of treatment instead of number of people included. Some participants may have been counted twice or included in both treatment group therefore analysis unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Permin-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-31 13:39:34 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Prayle-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-31 13:39:34 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics; comparison of morning vs evening intravenous tobramycin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:49 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Riethmueller-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:49 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Continuous vs intermittent infusions.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roberts-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomisation method unclear - participants appeared to have been randomised to single or combination therapy each morning using a cross-over method.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:50 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Semykin-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:50 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics; trial of inhaled tobramycin therapy.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stack-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with two other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-05-31 13:40:05 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Turner-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-05-31 13:40:05 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Not a comparison of single vs combination antibiotics; study of continuous vs intermittent infusion piperacillin-tazobactam.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wesley-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of single agent compared with 2 other antibiotics (i.e. drug A vs drug B plus drug C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-03 15:38:51 +0100" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Whitehead-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-03 15:38:51 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Efficacy of once daily tobramycin, not a comparison of single vs combination agents.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CXR: chest X-ray<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-03 15:57:36 +0000" MODIFIED_BY="Nikki Jahnke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-11-11 14:56:57 +0000" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:54:26 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Costantini-1982">
<DESCRIPTION>
<P>Randomly assigned, but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:54:56 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1982">
<DESCRIPTION>
<P>Mentions randomisation code, but no details given of how it was generated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-11 14:56:32 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Master-1997">
<DESCRIPTION>
<P>Randomization was stratified for age and disease<BR/>severity.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:57:42 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-McCarty-1988">
<DESCRIPTION>
<P>Treatment randomly assigned, no further details.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-11 14:56:57 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-McLauglin-1983">
<DESCRIPTION>
<P>Participants randomly selected, but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:59:56 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Parry-1977">
<DESCRIPTION>
<P>No discussion of how first participant was assigned to which treatment group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:00:31 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1986">
<DESCRIPTION>
<P>Described as randomised, but no details of method given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:03:09 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Smith-1999">
<DESCRIPTION>
<P>Computer-generated randomisation balance by FVC and center.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-11 14:56:53 +0000" MODIFIED_BY="Nikki Jahnke" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:54:43 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Costantini-1982">
<DESCRIPTION>
<P>Not directly discussed, but referred to as a controlled clinical trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:55:02 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1982">
<DESCRIPTION>
<P>Mentions randomisation code, but no details of how this may have been concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:57:07 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Master-1997">
<DESCRIPTION>
<P>The treatment code was broken only at the<BR/>completion of the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-11 14:56:53 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCarty-1988">
<DESCRIPTION>
<P>Used sequentially numbered envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 14:58:50 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McLauglin-1983">
<DESCRIPTION>
<P>Hospital pharmacist used consecutively numbered sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:00:04 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Parry-1977">
<DESCRIPTION>
<P>Alternation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:02:00 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Pedersen-1986">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-10 15:03:18 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Smith-1999">
<DESCRIPTION>
<P>Code generated by research pharmacist at the core center.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-11-10 15:03:19 +0000" MODIFIED_BY="Nikki Jahnke" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 14:54:45 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Costantini-1982">
<DESCRIPTION>
<P>Not discussed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 14:55:04 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Huang-1982">
<DESCRIPTION>
<P>Stated as double-blind, but no further details given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 14:57:14 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Master-1997">
<DESCRIPTION>
<P>Medical staff, nursing staff and participants were blinded to the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 14:57:47 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-McCarty-1988">
<DESCRIPTION>
<P>Not double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 14:58:52 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McLauglin-1983">
<DESCRIPTION>
<P>Neither participants or clinicians knew which regimen they were receiving.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 15:00:07 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-Parry-1977">
<DESCRIPTION>
<P>Drugs administered in different ways so clinicians and participants couldn't be blinded, no discussion of blinding of outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 15:02:04 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Pedersen-1986">
<DESCRIPTION>
<P>Both interventions given with same volume and in same way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-11-10 15:03:19 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Smith-1999">
<DESCRIPTION>
<P>Participants and clinicians blinded, serum concentrations monitored by unblinded 3rd party (research pharmacist).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-11-11 14:58:20 +0000" MODIFIED_BY="Nikki Jahnke" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 14:54:50 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Costantini-1982">
<DESCRIPTION>
<P>Not discussed, but appears to be no withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 14:55:16 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Huang-1982">
<DESCRIPTION>
<P>Not discussed, but appears to be no drop outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 14:57:17 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Master-1997">
<DESCRIPTION>
<P>Flow chart showing numbers randomized and included/excluded (with reasons) at each stage in paper.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 14:57:49 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-McCarty-1988">
<DESCRIPTION>
<P>Clear explanation of participants in groups, no drop outs occurred.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 14:59:11 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-McLauglin-1983">
<DESCRIPTION>
<P>2 participants in azlocillin plus placebo group withdrawn due to suspected drug-related complications; 2 participants discharged improved before completion of antibiotic course; 3 withdrawn due to incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-11 14:58:20 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="UNKNOWN" STUDY_ID="STD-Parry-1977">
<DESCRIPTION>
<P>No drop outs or withdrawals.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 15:02:10 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Pedersen-1986">
<DESCRIPTION>
<P>3 participants excluded - reasons given (bacteriological resistance developed between treatment arms in 2 participants and a 3rd withdrew on first day of 2nd treatment arm due to nausea).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-11-10 15:03:25 +0000" MODIFIED_BY="Nikki Jahnke" RESULT="YES" STUDY_ID="STD-Smith-1999">
<DESCRIPTION>
<P>35 participants withdrawn (21 from azlocillin group), reasons given in a table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-11-03 15:57:36 +0000" MODIFIED_BY="Nikki Jahnke" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-03 15:57:36 +0000" MODIFIED_BY="Nikki Jahnke" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-04-03 15:42:48 +0100" MODIFIED_BY="Nikki Jahnke">
<COMPARISON ID="CMP-001" MODIFIED="2008-09-17 10:29:30 +0100" MODIFIED_BY="Nikki Jahnke" NO="1">
<NAME>Single versus combination, symptomatic regimen</NAME>
<CONT_OUTCOME CHI2="0.16162392459120178" CI_END="18.935422550870836" CI_START="-8.990512410082584" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="4.972455070394127" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-09-17 10:28:52 +0100" MODIFIED_BY="Nikki Jahnke" NO="1" P_CHI2="0.9223671417860374" P_Q="0.8759531964207014" P_Z="0.485191461934918" Q="0.024367613586089444" RANDOM="NO" SCALE="83.13447045523485" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.6979771933396594">
<NAME>Mean FEV<SUB>1</SUB> at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.13725631100511237" CI_END="19.63711541845694" CI_START="-9.13916561436194" DF="1" EFFECT_SIZE="5.248974902047499" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="0.7110240953850477" P_Z="0.4745969680870532" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="42" WEIGHT="100.0" Z="0.7150195504439707">
<NAME>at 10 to 14 days</NAME>
<CONT_DATA CI_END="20.92664100192201" CI_START="-8.926641001922011" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="52.0" MEAN_2="46.0" ORDER="333" SD_1="25.0" SD_2="14.0" SE="7.615773105863909" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="92.91485756648584"/>
<CONT_DATA CI_END="49.45431620976048" CI_START="-58.65431620976048" EFFECT_SIZE="-4.600000000000001" ESTIMABLE="YES" MEAN_1="46.3" MEAN_2="50.9" ORDER="334" SD_1="115.2" SD_2="108.44" SE="27.579239535080248" STUDY_ID="STD-Smith-1999" TOTAL_1="36" TOTAL_2="30" WEIGHT="7.085142433514164"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="58.364808719713075" CI_START="-57.364808719713075" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.9864878992490294" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0" Z="0.016935716438930732">
<NAME>at 2 to 8 weeks</NAME>
<CONT_DATA CI_END="58.364808719713075" CI_START="-57.364808719713075" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="46.4" MEAN_2="45.9" ORDER="335" SD_1="94.96" SD_2="92.91" SE="29.523404091168665" STUDY_ID="STD-Smith-1999" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.03817585675487238" CI_END="15.036430242453184" CI_START="-10.840560620408484" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0979348110223497" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2008-09-17 10:29:00 +0100" MODIFIED_BY="Nikki Jahnke" NO="2" P_CHI2="0.9810930979738061" P_Q="0.8663388788187448" P_Z="0.750635313040595" Q="0.028328494516734738" RANDOM="NO" SCALE="69.14821729254565" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="60" UNITS="" WEIGHT="200.0" Z="0.31780176399242493">
<NAME>Mean FVC at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.009847362238137666" CI_END="15.121167897299639" CI_START="-11.439456527863445" DF="1" EFFECT_SIZE="1.8408556847180972" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.9209525787816207" P_Z="0.7858671765598851" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="42" WEIGHT="100.0" Z="0.271681176242613">
<NAME>at 10 to 14 days</NAME>
<CONT_DATA CI_END="15.647224204576801" CI_START="-11.647224204576801" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="69.0" ORDER="336" SD_1="24.0" SD_2="11.0" SE="6.962997438842939" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="94.69518949060324"/>
<CONT_DATA CI_END="56.65982866059943" CI_START="-58.65982866059943" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="72.7" MEAN_2="73.7" ORDER="337" SD_1="122.4" SD_2="116.1" SE="29.418820506607673" STUDY_ID="STD-Smith-1999" TOTAL_1="36" TOTAL_2="30" WEIGHT="5.304810509396754"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.198538050386263E-34" CI_END="64.2969616392197" CI_START="-50.496961639219705" DF="0" EFFECT_SIZE="6.8999999999999995" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.0" P_Z="0.8137291834889877" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0" Z="0.2356178987022461">
<NAME>at 2 to 8 weeks</NAME>
<CONT_DATA CI_END="64.2969616392197" CI_START="-50.496961639219705" EFFECT_SIZE="6.899999999999999" ESTIMABLE="YES" MEAN_1="70.5" MEAN_2="63.6" ORDER="338" SD_1="108.87" SD_2="78.49" SE="29.284702214918035" STUDY_ID="STD-Smith-1999" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean RV at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="82.20859764167311" CI_START="-78.20859764167311" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="281.0" MEAN_2="279.0" ORDER="339" SD_1="126.0" SD_2="86.0" SE="40.92350587783668" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-09-17 10:29:12 +0100" MODIFIED_BY="Nikki Jahnke" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="20.269539964566704" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean TLC at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="14.116308263515345" CI_START="-16.116308263515343" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="117.0" MEAN_2="118.0" ORDER="340" SD_1="21.0" SD_2="19.0" SE="7.712543895066876" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.01404265611525169" CI_END="27.778546064166335" CI_START="-33.546469250972756" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8839615934032117" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-09-17 10:29:17 +0100" MODIFIED_BY="Nikki Jahnke" NO="5" P_CHI2="0.9056701399242265" P_Q="0.9056701399242265" P_Z="0.8537433030926105" Q="0.01404265611525169" RANDOM="NO" SCALE="77.10953499934493" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="57" TOTAL_2="47" UNITS="" WEIGHT="200.0" Z="0.1843443764936701">
<NAME>Mean RV/TLC at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="37.875940144000815" CI_START="-40.67594014400081" DF="0" EFFECT_SIZE="-1.3999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.944302407556157" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="29" WEIGHT="100.0" Z="0.0698633710178723">
<NAME>at 2 weeks</NAME>
<CONT_DATA CI_END="37.875940144000815" CI_START="-40.67594014400081" EFFECT_SIZE="-1.3999999999999986" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="44.1" ORDER="341" SD_1="88.15" SD_2="72.16" SE="20.039113194836442" STUDY_ID="STD-Smith-1999" TOTAL_1="35" TOTAL_2="29" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="43.866845420992966" CI_START="-54.26684542099297" DF="0" EFFECT_SIZE="-5.200000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="0.835453208984769" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="0.20771281773186462">
<NAME>At 2 to 8 weeks</NAME>
<CONT_DATA CI_END="43.866845420992966" CI_START="-54.26684542099297" EFFECT_SIZE="-5.200000000000003" ESTIMABLE="YES" MEAN_1="45.9" MEAN_2="51.1" ORDER="342" SD_1="73.64" SD_2="82.73" SE="25.034564822632447" STUDY_ID="STD-Smith-1999" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.19177984493515327" CI_END="17.47856625176174" CI_START="-11.150179079591723" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="3.1641935860850094" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.908564085426363" P_Q="0.9780479419508102" P_Z="0.6648329811520972" Q="7.571466372039933E-4" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="59" UNITS="" WEIGHT="200.0" Z="0.4332502453083273">
<NAME>Mean PFR at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.1910226982979493" CI_END="17.907236743528866" CI_START="-11.485384915346879" DF="1" EFFECT_SIZE="3.210925914090994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.6620668021452448" P_Z="0.668488732389181" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="41" WEIGHT="100.00000000000001" Z="0.4282230569075012">
<NAME>at 10 to 14 days</NAME>
<CONT_DATA CI_END="19.116308263515343" CI_START="-11.116308263515345" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="67.0" MEAN_2="63.0" ORDER="343" SD_1="21.0" SD_2="19.0" SE="7.712543895066876" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="94.52031884785413"/>
<CONT_DATA CI_END="52.381354945657485" CI_START="-73.18135494565746" EFFECT_SIZE="-10.399999999999991" ESTIMABLE="YES" MEAN_1="54.7" MEAN_2="65.1" ORDER="344" SD_1="117.73" SD_2="135.17" SE="32.03189213723762" STUDY_ID="STD-Smith-1999" TOTAL_1="35" TOTAL_2="29" WEIGHT="5.47968115214588"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="65.49826272775924" CI_START="-60.898262727759246" DF="0" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.9431353073223355" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="0.07132976398197824">
<NAME>At 2 to 8 weeks</NAME>
<CONT_DATA CI_END="65.49826272775924" CI_START="-60.898262727759246" EFFECT_SIZE="2.299999999999997" ESTIMABLE="YES" MEAN_1="61.9" MEAN_2="59.6" ORDER="345" SD_1="106.47" SD_2="97.16" SE="32.24460409796255" STUDY_ID="STD-Smith-1999" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2686214957978789" CI_END="21.802176686901" CI_START="-8.275470599436174" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="6.763353043732414" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.8743183370686879" P_Q="0.8077246053874563" P_Z="0.3780758516070807" Q="0.059225299108735446" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="59" UNITS="" WEIGHT="200.0" Z="0.8814471593638519">
<NAME>Mean MMEF at end of course (% pred)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.2093961966891435" CI_END="22.55004055767938" CI_START="-8.218358721893907" DF="1" EFFECT_SIZE="7.165840917892736" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.6472410838904332" P_Z="0.3612761979647988" STUDIES="2" TAU2="0.0" TOTAL_1="50" TOTAL_2="41" WEIGHT="99.99999999999999" Z="0.9129360283189869">
<NAME>at 10 to 14 days</NAME>
<CONT_DATA CI_END="23.793629288115042" CI_START="-7.793629288115042" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="22.0" ORDER="346" SD_1="27.0" SD_2="14.0" SE="8.058122196475637" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="94.88245961897384"/>
<CONT_DATA CI_END="59.70553600186015" CI_START="-76.30553600186015" EFFECT_SIZE="-8.3" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="33.5" ORDER="347" SD_1="111.81" SD_2="156.7" SE="34.69733961352308" STUDY_ID="STD-Smith-1999" TOTAL_1="35" TOTAL_2="29" WEIGHT="5.117540381026151"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="69.47424266831368" CI_START="-73.27424266831369" DF="0" EFFECT_SIZE="-1.8999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.02" NO="2" P_CHI2="1.0" P_Z="0.958389471047336" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0" Z="0.05217472622346051">
<NAME>At 2 to 8 weeks</NAME>
<CONT_DATA CI_END="69.47424266831368" CI_START="-73.27424266831369" EFFECT_SIZE="-1.8999999999999986" ESTIMABLE="YES" MEAN_1="25.8" MEAN_2="27.7" ORDER="348" SD_1="94.75" SD_2="128.55" SE="36.41609908717946" STUDY_ID="STD-Smith-1999" TOTAL_1="22" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-09-17 10:29:30 +0100" MODIFIED_BY="Nikki Jahnke" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="17.44478343430271" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean Schwachman score at end of course</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="12.868180232676949" CI_START="-6.8681802326769485" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="71.0" MEAN_2="68.0" ORDER="349" SD_1="13.0" SD_2="13.0" SE="5.034878350069642" STUDY_ID="STD-McLauglin-1983" TOTAL_1="15" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5442060389034507" CI_END="14.939678178676468" CI_START="2.1189028843233055" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.626342256178478" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="1.174341242276547" LOG_CI_START="0.3261110521477815" LOG_EFFECT_SIZE="0.7502261472121643" METHOD="PETO" NO="9" P_CHI2="0.7617757966024621" P_Q="1.0" P_Z="5.262594451003543E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="32" WEIGHT="100.0" Z="3.4670216785678676">
<NAME>Number of Pseudomonas isolates eradicated at end of course</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_DATA CI_END="71.64847852494478" CI_START="1.4399259910136726" EFFECT_SIZE="10.157189889169786" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.8552069724690705" LOG_CI_START="0.15834017090055186" LOG_EFFECT_SIZE="1.0067735716848112" ORDER="350" O_E="2.3333333333333335" SE="0.996747958867483" STUDY_ID="STD-Costantini-1982" TOTAL_1="11" TOTAL_2="7" VAR="1.0065359477124183" WEIGHT="24.988025794391753"/>
<DICH_DATA CI_END="78.01625177722471" CI_START="0.5144744067882776" EFFECT_SIZE="6.335405658119502" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.892185081177368" LOG_CI_START="-0.2886362249192074" LOG_EFFECT_SIZE="0.8017744281290804" ORDER="351" O_E="1.125" SE="1.281025230440697" STUDY_ID="STD-Huang-1982" TOTAL_1="10" TOTAL_2="6" VAR="0.609375" WEIGHT="15.12820108716879"/>
<DICH_DATA CI_END="15.07349971787496" CI_START="1.2080682156840261" EFFECT_SIZE="4.26729608865929" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="1.178214097152316" LOG_CI_START="0.0820914581747676" LOG_EFFECT_SIZE="0.6301527776635418" ORDER="352" O_E="3.5" SE="0.6438678640299826" STUDY_ID="STD-McCarty-1988" TOTAL_1="19" TOTAL_2="19" VAR="2.4121621621621623" WEIGHT="59.88377311843946"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean change Pseudomonas density in cfu/g at end of course</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.307716177684054" CI_START="-9.507716177684056" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="6.9" ORDER="353" SD_1="19.67" SD_2="15.5" SE="4.034623207395192" STUDY_ID="STD-Smith-1999" TOTAL_1="43" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.824725517678907" CI_END="3.707019189656087" CI_START="0.584509273832158" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.4720010511639434" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.5690248341925466" LOG_CI_START="-0.2332085939252696" LOG_EFFECT_SIZE="0.16790812013363848" METHOD="PETO" NO="11" P_CHI2="0.5664821547413117" P_Q="0.521621177922083" P_Z="0.4119629537735533" Q="4.195534682144091" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="212" TOTAL_2="178" WEIGHT="600.0" Z="0.8204441665959233">
<NAME>Number adverse events</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6291908355348165" CI_END="2.355823852364768" CI_START="0.0909791529197384" DF="1" EFFECT_SIZE="0.462958808660405" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.11.01" LOG_CI_END="0.37214281463547816" LOG_CI_START="-1.0410581110760346" LOG_EFFECT_SIZE="-0.3344576482202782" NO="1" P_CHI2="0.4276524975109045" P_Z="0.35355463127140285" STUDIES="2" TAU2="0.0" TOTAL_1="68" TOTAL_2="63" WEIGHT="100.00000000000001" Z="0.9277165517503058">
<NAME>local erythema / irritation</NAME>
<DICH_DATA CI_END="5.570326221372425" CI_START="0.002108247881778089" EFFECT_SIZE="0.10836802322189587" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7458806300019644" LOG_CI_START="-2.6760783273497504" LOG_EFFECT_SIZE="-0.965098848673893" ORDER="354" O_E="-0.55" SE="2.010075630518424" STUDY_ID="STD-McCarty-1988" TOTAL_1="11" TOTAL_2="9" VAR="0.24750000000000003" WEIGHT="17.055255655346883"/>
<DICH_DATA CI_END="3.7245092597399614" CI_START="0.10455936204686281" EFFECT_SIZE="0.6240451202725998" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5710690583387917" LOG_CI_START="-0.9806370752015405" LOG_EFFECT_SIZE="-0.20478400843137443" ORDER="355" O_E="-0.5675675675675675" SE="0.9114798639108309" STUDY_ID="STD-Smith-1999" TOTAL_1="57" TOTAL_2="54" VAR="1.2036655820439603" WEIGHT="82.94474434465313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="316.6691886965229" CI_START="0.11985243229243792" DF="0" EFFECT_SIZE="6.160647084304638" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="2.5006058094090426" LOG_CI_START="-0.9213531479426722" LOG_EFFECT_SIZE="0.789626330733185" NO="2" P_CHI2="1.0" P_Z="0.3657123064533152" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="100.0" Z="0.9045340337332907">
<NAME>generalised rash</NAME>
<DICH_DATA CI_END="316.6691886965229" CI_START="0.11985243229243792" EFFECT_SIZE="6.160647084304638" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5006058094090426" LOG_CI_START="-0.9213531479426722" LOG_EFFECT_SIZE="0.789626330733185" ORDER="356" O_E="0.44999999999999996" SE="2.010075630518424" STUDY_ID="STD-McCarty-1988" TOTAL_1="11" TOTAL_2="9" VAR="0.24750000000000003" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.137977237155086" CI_START="0.04617338676800046" DF="0" EFFECT_SIZE="0.8079593375216034" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="1.1503872780901765" LOG_CI_START="-1.3356082692498126" LOG_EFFECT_SIZE="-0.0926104955798181" NO="3" P_CHI2="1.0" P_Z="0.8838988037996762" STUDIES="1" TAU2="0.0" TOTAL_1="11" TOTAL_2="9" WEIGHT="100.0" Z="0.14602860903839363">
<NAME>fever</NAME>
<DICH_DATA CI_END="14.13797723715508" CI_START="0.04617338676800048" EFFECT_SIZE="0.8079593375216034" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1503872780901763" LOG_CI_START="-1.3356082692498124" LOG_EFFECT_SIZE="-0.0926104955798181" ORDER="357" O_E="-0.10000000000000009" SE="1.4602860903839352" STUDY_ID="STD-McCarty-1988" TOTAL_1="11" TOTAL_2="9" VAR="0.4689473684210527" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="15.561056751389172" CI_START="0.15316768289635718" DF="0" EFFECT_SIZE="1.5438429343780393" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="1.1920390865941173" LOG_CI_START="-0.8148328575515074" LOG_EFFECT_SIZE="0.18860311452130493" NO="4" P_CHI2="1.0" P_Z="0.7125827997745582" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="35" WEIGHT="100.00000000000001" Z="0.3683895356773374">
<NAME>renal impairment (increased creatinine by 50%)</NAME>
<DICH_DATA CI_END="15.561056751389172" CI_START="0.15316768289635718" EFFECT_SIZE="1.5438429343780393" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.1920390865941173" LOG_CI_START="-0.8148328575515074" LOG_EFFECT_SIZE="0.18860311452130493" ORDER="358" O_E="0.3125" SE="1.1788465141674798" STUDY_ID="STD-Smith-1999" TOTAL_1="45" TOTAL_2="35" VAR="0.7195905854430381" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="305.43890940524125" CI_START="0.1122680382156681" DF="0" EFFECT_SIZE="5.855854092586292" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.11.05" LOG_CI_END="2.484924360368177" LOG_CI_START="-0.9497438661985427" LOG_EFFECT_SIZE="0.7675902470848172" NO="5" P_CHI2="1.0" P_Z="0.38100960779907234" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="33" WEIGHT="100.0" Z="0.8760375907831333">
<NAME>auditory impairment</NAME>
<DICH_DATA CI_END="305.4389094052418" CI_START="0.112268038215668" EFFECT_SIZE="5.855854092586292" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.484924360368178" LOG_CI_START="-0.9497438661985431" LOG_EFFECT_SIZE="0.7675902470848172" ORDER="359" O_E="0.4342105263157895" SE="2.017541118167216" STUDY_ID="STD-Smith-1999" TOTAL_1="43" TOTAL_2="33" VAR="0.24567174515235457" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.29866642027857" CI_START="0.6780314054637726" DF="0" EFFECT_SIZE="3.6173335368082924" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" ID="CMP-001.11.06" LOG_CI_END="1.2855272993536515" LOG_CI_START="-0.16875018975574135" LOG_EFFECT_SIZE="0.5583885547989551" NO="6" P_CHI2="1.0" P_Z="0.13229662534463651" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="29" WEIGHT="100.00000000000001" Z="1.5051067832392178">
<NAME>proteinuria</NAME>
<DICH_DATA CI_END="19.29866642027857" CI_START="0.6780314054637726" EFFECT_SIZE="3.6173335368082924" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.2855272993536515" LOG_CI_START="-0.16875018975574135" LOG_EFFECT_SIZE="0.5583885547989551" ORDER="360" O_E="1.7619047619047619" SE="0.854249795892529" STUDY_ID="STD-Smith-1999" TOTAL_1="34" TOTAL_2="29" VAR="1.3703459878575088" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.392824966811844" CI_END="0.6157859172578164" CI_START="0.11394724521029873" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.26489074900952114" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.21057024743534683" LOG_CI_START="-0.9432961698642807" LOG_EFFECT_SIZE="-0.5769332086498138" METHOD="PETO" NO="12" P_CHI2="0.5308185858221051" P_Q="0.5308185858221046" P_Z="0.002025483442674933" Q="0.3928249668118449" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="53" TOTAL_2="39" WEIGHT="200.0" Z="3.0864700587918374">
<NAME>Number readmitted</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3010497884298515" CI_START="0.014077584925353308" DF="0" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.11429391641294032" LOG_CI_START="-1.8514718440259474" LOG_EFFECT_SIZE="-0.8685889638065036" NO="1" P_CHI2="1.0" P_Z="0.08326451666320515" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="6" WEIGHT="100.0" Z="1.732050807568877">
<NAME>in 1 month</NAME>
<DICH_DATA CI_END="1.3010497884298509" CI_START="0.014077584925353308" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.1142939164129401" LOG_CI_START="-1.8514718440259474" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="361" O_E="-1.5" SE="1.1547005383792515" STUDY_ID="STD-Huang-1982" TOTAL_1="10" TOTAL_2="6" VAR="0.75" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7327278674066724" CI_START="0.11893553831032612" DF="0" EFFECT_SIZE="0.2952073565224787" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="-0.13505729088109386" LOG_CI_START="-0.9246883574421694" LOG_EFFECT_SIZE="-0.5298728241616316" NO="2" P_CHI2="1.0" P_Z="0.00852788176542376" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="33" WEIGHT="100.0" Z="2.6304224737920587">
<NAME>in 80 days</NAME>
<DICH_DATA CI_END="0.7327278674066724" CI_START="0.11893553831032612" EFFECT_SIZE="0.2952073565224787" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="-0.13505729088109386" LOG_CI_START="-0.9246883574421694" LOG_EFFECT_SIZE="-0.5298728241616316" ORDER="362" O_E="-5.671052631578949" SE="0.4638331972347945" STUDY_ID="STD-Smith-1999" TOTAL_1="43" TOTAL_2="33" VAR="4.648109418282548" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean time to next course of antibiotics (weeks)</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours combination</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.66609774884565" CI_START="-9.666097748845651" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="24.0" ORDER="363" SD_1="17.0" SD_2="30.0" SE="8.503267345882731" STUDY_ID="STD-McLauglin-1983" TOTAL_1="18" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="33" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean WBC count at end of course</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.693664200051495" CI_START="-7.193664200051495" EFFECT_SIZE="-0.75" ESTIMABLE="YES" MEAN_1="7.43" MEAN_2="8.18" ORDER="364" SD_1="15.34" SD_2="13.27" SE="3.287644186769908" STUDY_ID="STD-Smith-1999" TOTAL_1="43" TOTAL_2="33" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="19.28661078885885" CI_END="1.3347162605823444" CI_START="0.508096074612186" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8235071904500558" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="77" I2="68.89033503249844" I2_Q="66.13170728788805" ID="CMP-001.15" LOG_CI_END="0.12538895142310344" LOG_CI_START="-0.2940541602970498" LOG_EFFECT_SIZE="-0.08433260443697321" METHOD="PETO" NO="15" P_CHI2="0.003706013485200277" P_Q="0.03124191722138081" P_Z="0.4306178379471314" Q="8.857842423592679" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="179" TOTAL_2="165" WEIGHT="400.0" Z="0.7881348521427561">
<NAME>Number resistant strains</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Single</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours combination</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours single</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7654241196233308" CI_END="1.8233667457787748" CI_START="0.37781193874618" DF="1" EFFECT_SIZE="0.8299938103793257" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.26087402995438735" LOG_CI_START="-0.42272432261941334" LOG_EFFECT_SIZE="-0.08092514633251298" NO="1" P_CHI2="0.38163640851396063" P_Z="0.6426151433166432" STUDIES="2" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.00000000000001" Z="0.464045507594273">
<NAME>at baseline</NAME>
<DICH_DATA CI_END="7.064686045861167" CI_START="0.32019910264711293" EFFECT_SIZE="1.5040299639197108" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.8490928665979276" LOG_CI_START="-0.49457988951838444" LOG_EFFECT_SIZE="0.1772564885397716" ORDER="365" O_E="0.6551724137931032" SE="0.7892800282301351" STUDY_ID="STD-McLauglin-1983" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="25.883022602615764"/>
<DICH_DATA CI_END="1.6824138549592513" CI_START="0.27032937742289254" EFFECT_SIZE="0.6743929788919685" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.22593283618062662" LOG_CI_START="-0.5681067557833984" LOG_EFFECT_SIZE="-0.1710869598013859" ORDER="366" O_E="-1.8108108108108105" SE="0.4664227868790398" STUDY_ID="STD-Smith-1999" TOTAL_1="57" TOTAL_2="54" VAR="4.596639883126369" WEIGHT="74.11697739738425"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.549860884877516" CI_END="6.317576705103732" CI_START="0.9404254404632097" DF="1" EFFECT_SIZE="2.437459713627548" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="31" I2="89.52864327496613" ID="CMP-001.15.02" LOG_CI_END="0.8005505236273383" LOG_CI_START="-0.02667563081959591" LOG_EFFECT_SIZE="0.3869374464038712" NO="2" P_CHI2="0.001999663473789659" P_Z="0.06671967014958409" STUDIES="2" TAU2="0.0" TOTAL_1="54" TOTAL_2="45" WEIGHT="100.0" Z="1.8335577402736356">
<NAME>at end of course</NAME>
<DICH_DATA CI_END="1.6750605567996044" CI_START="0.07592027213736241" EFFECT_SIZE="0.35661050646158454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2240305122734698" LOG_CI_START="-1.1196422438428424" LOG_EFFECT_SIZE="-0.4478058657846862" ORDER="367" O_E="-1.6551724137931032" SE="0.7892800282301351" STUDY_ID="STD-McLauglin-1983" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="37.90194445980668"/>
<DICH_DATA CI_END="26.3816889751556" CI_START="2.352632603935215" EFFECT_SIZE="7.878224522684619" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="19" LOG_CI_END="1.4213025959529408" LOG_CI_START="0.3715541113912531" LOG_EFFECT_SIZE="0.8964283536720971" ORDER="368" O_E="5.428571428571431" SE="0.6166274561703394" STUDY_ID="STD-Smith-1999" TOTAL_1="40" TOTAL_2="30" VAR="2.6299911268855367" WEIGHT="62.09805554019332"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.11348336076532961" CI_END="1.1358610736350745" CI_START="0.17041622153016886" DF="1" EFFECT_SIZE="0.439964944458181" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" I2="0.0" ID="CMP-001.15.03" LOG_CI_END="0.055325216372103615" LOG_CI_START="-0.7684890681037391" LOG_EFFECT_SIZE="-0.3565819258658177" NO="3" P_CHI2="0.7362127489843014" P_Z="0.08975114988626945" STUDIES="2" TAU2="0.0" TOTAL_1="40" TOTAL_2="36" WEIGHT="100.0" Z="1.6967118570409505">
<NAME>at 2 to 8 weeks</NAME>
<DICH_DATA CI_END="1.6750605567996044" CI_START="0.07592027213736241" EFFECT_SIZE="0.35661050646158454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.2240305122734698" LOG_CI_START="-1.1196422438428424" LOG_EFFECT_SIZE="-0.4478058657846862" ORDER="369" O_E="-1.6551724137931032" SE="0.7892800282301351" STUDY_ID="STD-McLauglin-1983" TOTAL_1="14" TOTAL_2="15" VAR="1.6052318668252084" WEIGHT="37.58993830673853"/>
<DICH_DATA CI_END="1.6586851817805144" CI_START="0.1503009025400819" EFFECT_SIZE="0.4993013917980513" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.219763964812917" LOG_CI_START="-0.8230384115155509" LOG_EFFECT_SIZE="-0.301637223351317" ORDER="370" O_E="-1.8510638297872344" SE="0.6125472778103558" STUDY_ID="STD-Smith-1999" TOTAL_1="26" TOTAL_2="21" VAR="2.665144566693566" WEIGHT="62.41006169326147"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1812242347344302" CI_START="0.06182877521261791" DF="0" EFFECT_SIZE="0.27024738238342233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="0.07233234864138474" LOG_CI_START="-1.2088093565040356" LOG_EFFECT_SIZE="-0.5682385039313255" NO="4" P_CHI2="1.0" P_Z="0.08209676093599005" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="1.7386476419607348">
<NAME>Difference between baseline and 2 to 8 weeks</NAME>
<DICH_DATA CI_END="1.1812242347344302" CI_START="0.06182877521261791" EFFECT_SIZE="0.27024738238342233" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.07233234864138474" LOG_CI_START="-1.2088093565040356" LOG_EFFECT_SIZE="-0.5682385039313255" ORDER="371" O_E="-2.3103448275862073" SE="0.7525489793561388" STUDY_ID="STD-McLauglin-1983" TOTAL_1="14" TOTAL_2="15" VAR="1.765755053507729" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>